CN1094063C - 制备单体卡利许霉素衍生物/载体的共轭物的方法 - Google Patents
制备单体卡利许霉素衍生物/载体的共轭物的方法 Download PDFInfo
- Publication number
- CN1094063C CN1094063C CN96194451A CN96194451A CN1094063C CN 1094063 C CN1094063 C CN 1094063C CN 96194451 A CN96194451 A CN 96194451A CN 96194451 A CN96194451 A CN 96194451A CN 1094063 C CN1094063 C CN 1094063C
- Authority
- CN
- China
- Prior art keywords
- coor
- conhr
- group
- alkyl
- key
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供制备有较高药物负荷量/得率和减少凝集量的单体卡利许霉素衍生物/载体共轭物的方法。共轭物的制备是在溶液中约25℃至37℃培育卡利许霉素衍生物和蛋白质载体约15分钟至24小时,溶液包括非亲核,蛋白质相容的缓冲液,选自丙二醇,乙醇,DMSO,及其组合的助溶剂和至少包括一个C6-C18羧酸的添加剂,其pH范围约为4.0至8.5,和回收单体卡利许霉素衍生物/载体共轭物。共轭物还可在包括非亲核,蛋白质相容的缓冲液和助溶剂叔丁醇的溶液中培育卡利许霉素衍生物和蛋白质载体。
Description
发明领域
本发明涉及一种制备单体卡利许霉素衍生物/载体的共轭物的方法。
发明背景
自从1970年代公开了发现制备单克隆抗体的方法(G.Kohler和C.Milstein;自然,256:495(1975))以来,人们曾作了许多尝试用这些蛋白质选择性地定向结合目标抗肿瘤试剂来抗肿瘤。(如见,T.Ghose和A.H.Blair,CRC关键Rev.药物载体系统(CRC Critical Rev.Drug Carrier Systems),3:263,1987,G.A.Koppel,生物共轭化学(Bioconjugate Chem.1:13,1990和J.Upeslacis和L.Hinman,Ann.Rep.Med.Chem.23:151,1988)。尽管该领域仍有进展,但是许多经典的抗肿瘤试剂由于多种原因而产生了效率相当低的抗体共轭物。低效率的一个原因是缺少化学治疗的效力。
有效的抗菌和抗肿瘤试剂类被称为卡利许霉素或LL-E33288混合物,在美国专利No.4,970,188(1990)中有所描述。最有效的试剂是命名为γ1 1,这里只简单参照为γ。这些化合物含有一个甲基三硫化物,它可与合适的硫醇反应形成二硫键,同时加入一个有用于使卡利许霉素衍生物与载体连接的官能团如酰肼或其它官能团。这些与卡利许霉素反应的例子在美国专利No.5,053,394中有所描述,其中也公开了卡利许霉素的定向(靶向)形式。
限制上述共轭物的用途的因素是当可与载体共轭连接的卡利许霉素衍生物的量(即药物负荷量)增加时,它们易形成凝聚体。理想的是在载体上应有尽可能多的药物负荷,且其同时应保持对载体蛋白的亲和性,因为较高的药物负荷可提高共轭物的固有的效率。凝聚体必须在治疗过程中被除去,凝聚体的存在也将使这些共轭物的规模放大制备更困难,并降低产物的得率。因此,卡利许霉素在载体蛋白上的负荷量(药物负荷量),在共轭反应中形成的凝聚体的量,以及最终可获得的纯化的单体共轭物的得率均有关联。因此,在较高的药物负荷量和最终单体的得率间必须通过调节加入共轭反应的起反应的卡利许霉素衍生物的量来进行折衷。
用欧洲专利No.0689845中描述的连接剂进行共轭反应时卡利许霉素共轭物有凝集趋势特别成问题。在这种情况下,生成的共轭物很大部分是以凝集的形式存在难以进行纯化以用于治疗给药。对于一些载体蛋白来说,除非小规模制备否则甚至不可能制成适中负荷的共轭物,因此,非常有必要有一种使胞毒药物如卡利许霉素与载体共轭结合以减少凝集量从而使药物负荷尽可能高且有合理的产物得率的方法。好的生物活性所需的实际药物负荷,在纯化过程中可完全除去的凝集量和最后可获得的共轭物的得率需要个别一一测定。
发明概要
本发明的卡利许霉素衍生物/载体共轭物有下列化学式
Pr(-X-S-S-W)m
其中:
Pr为一种蛋白质载体,
X是一种连接剂,它包括任何可与蛋白质载体反应的反应基团的产物,
W是通过除去天然存在的甲基三硫化物基团后形成的卡利许霉素基团;和
m是0.5至15的数。
本发明含制备有较高药物负荷/得率和减少凝集的单体卡利许霉素衍生物/载体的方法包括步骤:
(1)使卡利许霉素衍生物和蛋白质载体在一个非亲核的,蛋白质相容的,适当pH范围约为4.0至8.5的缓冲液中培育,溶液还包括(a)一个选自丙二醇,乙醇,DMSO,及其组合的一种助溶剂,和(b)一种至少包括一个C6-C18羧酸的添加剂,在约25℃至约37℃在其中培育约15分钟至约24小时;和
(2)纯化步骤(1)生成的共轭物以生产单体共轭物。
本发明制备有较高药物负荷/得率和减少凝集的单体卡利许霉素衍生物/载体的另一种方法包括步骤:
(1)使卡利许霉素衍生物和蛋白质载体在一个非亲核的,蛋白质相容的,适当pH范围约为4.0至8.5的缓冲液中培育,溶液还包括叔丁醇助溶剂,在其中培育在约25℃至约37℃进行约15分钟至约24小时;和
(2)纯化步骤(1)生成的共轭物以生产单体共轭物。
发明详细描述
本发明的共轭物包括一种用连接剂衍生的治疗试剂,连接剂包括任何与蛋白质靶载体反应的(活性)反应基团利用。特殊的助溶剂和添加剂可诱导形成这些共轭物的单体而不是凝集形式,并可允许有较高的药物负荷/得率而没有过多的凝集。单体形式有医疗价值。
载体
本发明的载体最好是蛋白质载体。载体分子包括生长因子,抗体,抗体片段,及其基因工程或酶工程生产的类似物,后面或以单独名称提及或总称为载体基团。载体必要的性质是它应能识别抗原或与不需要的细胞连接的受体。美国专利No.5,053,394给出了载体的例子,这些载体也适用于本发明。用于本发明的较佳的载体是人的或人化的抗体。
这里例举的具体的载体例子是抗体P67.6,A33,CT-M-01(也称为7F11C7)和Waldman的“antiTac”抗体。这些抗体在这里以两种型式使用:一种是鼠型,用“m”标明(如m-P67.6),和另一种基因工程生产的人化型,其在合适情况下用“h”际明(如h-P67.6)。抗体人化的基础技术在Winter的美国专利No.5,225,539(1993)和Adair的PCT公开号WO91/09967(1987)中公开。m-P67.6在I.D.Bernstein等人的临床研究杂志(J.Clin.Invest.)的79卷:1153页(1987)和I.D.Bernstein等人的免疫学杂志(J.Immunol.)128卷:867-881页(1992)中公开,它可识别CD33抗原该,抗原在某些人骨髓肿瘤占优势(很丰富),特别是急性非淋巴细胞白血病(ANLL)。另一种可用的抗体是MOPC-21,它是一种非靶向性抗体,它的共轭物可用作显示另一种抗体共轭物的靶向作用的对照品。这种鼠型抗体公开在Melchers,F.,生物化学杂志(Biochem.J.)119卷:765-772页中。
欧洲专利申请号No.0689845公开了本发明最常采用的一种特殊的h-P67.6的DNA编码并预测了其不同部位的氨基酸顺序。该抗体的构架是人IgG4的EU构架,见Gottlieb等人的论文生物化学(Biochemistry)9卷:3115至3161页(1970)。抗体用PCT申请号No.WO91/09967中描述的常用方法制备。
欧洲专利申请号No.86401482.4/0208615中公开了抗体m-CT-M-01,它可识别许多人类固体肿瘤,特别是乳房,肺和卵巢肿瘤上的聚上皮细胞粘蛋白(PEM)抗原。在PCT公开号No.WO93/06231(1993)中描述了该抗体的人化型h-CT-M-01。在美国专利No.5,160,723和5,431,897中公开了抗体m-A33,它是一种可识别在结肠癌细胞上的糖蛋白抗原的鼠型抗体。PCT专利公开号No.WO94/13805(1994年6月23日)中公开了该抗体的人化型h-A33。在T.A.Waldman等人的论文免疫学杂志(J.Immunol.)126卷:1393页(1981)中公开了Anti-Tac,它是一种与激活的和有功能作用的成熟T细胞(其中包括激活的白血病细胞)上的IL-2受体反应的鼠型抗体。
治疗试剂
本发明适用的治疗试剂是结合到DNA上并破坏DNA的胞毒抗生素。较佳的胞毒试剂是甲基三硫化物抗肿瘤抗生素卡利许霉素。适用于本发明的卡利许霉素的例子公开在如美国专利No.5,503,394中。也可参见美国专利No.4,671,958;4,970,198;5,037,651和5,079,233。较佳的卡利许霉素是N-乙酰基γ卡利许霉素类的γ卡利许霉素。N-乙酰基γ卡利许霉素的共轭态的结构如下表示。
卡利许霉素衍生物/载体共轭物
本发明的共轭物有下列化学式
Pr(-X-S-S-W)m
其中:
Pr为一种蛋白质载体,
X是一种连接剂,它包括有任何可与蛋白质载体反应的反应基团的产物,
W是通过除去天然存在的甲基三硫化物基团后形成的卡利许霉素基团;和
m是0.5至15的数。
X最好有化学式Z-Sp,其中:
Sp是直链或支链的二价或三价(C1-C18)基团,二价或三价芳基或杂芳基团,二价或三价(C3-C18)的环烷基或杂环烷基基团,二价或三价的芳基-芳基或杂芳基-芳基(C1-C18)基团,二价或三价的环烷基-烷基或杂环烷基-烷基(C1-C18)基团或二价或三价(C2-C18)不饱和烷基基团,其中杂芳基最好是呋喃基,噻嗯基,N-甲基吡咯基,吡啶基(pyridinly),N-甲基咪唑基,噁唑基,嘧啶基,喹啉基,异喹啉基,N-甲基咔唑基,氨基香豆素基或吩嗪基,其中如果Sp是三价基团,Sp还可被低碳(C1-C5)二烷基氨基,低碳(C1-C5)烷氧基,羟基,或低碳(C1-C5)硫代烷基基团替代;和
Z是-NHC(=O)-,-CH=NNHC(=O)-,-CH2NHNHC(=O)-,-CH=NNHC(=O)NH-,-CH2NHNHC(=O)NH-,-CH=NNHC(=S)NH-,-CH2NHNHC(=S)NH-,-CH=N-,-CH2NH-,-OC(=O)-,-SS-,
或者X的化学式为
(CO-Alk1-Sp1-Ar-Sp2-Alk2-C(Z1)=Q-Sp)
其中Alk1和Alk2各自代表一个键或有支链或无支链的(C1-C10)的亚烷基链;
Sp1是一个键,-S-,-O-,-CONH-,-NHCO-,-NR′-,-N(CH2CH2)2N-,或-X-Ar′-Y-(CH2)n-Z,其中X,Y,和Z各自为一个键,-NR′-,-S-或-O-,限制条件是当n=0时,Y和Z中的至少一个为一个键,且Ar′是1,2-,1,3-,或1,4-亚苯基,它可任意被(C1-C5)烷基,(C1-C4)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,-O(CH2)nCONHR′,或-S(CH2)nCONHR′中的一个,两个或三个基团取代,限制条件是当Alk1是一个键时,Sp1是一个键;
n是0至5间的整数;
R′是有支链或无支链的(C1-C5)链,它可任意被-OH,(C1-C4)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,(C1-C3)二烷基氨基,或(C1-C3)三烷基铵-A-中的一个或两个基团取代,其中A-是药学上可接受的成盐阴离子;
Ar是1,2-,1,3-,或1,4-亚苯基,它可任意被(C1-C6)烷基,(C1-C5)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,-O(CH2)nCONHR′,或-S(CH2)nCONHR′中的一个,两个或三个基团取代,其中n和R′是如前面所确定的,或Ar为1,2-,1,3-,1,4-,1,5-,1,6-,1,7-,1,8-,2,3-,2,6-,或2,7-亚萘基或
每个亚萘基或吩噻嗪可任意被(C1-C6)烷基,(C1-C5)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′-,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,或-S(CH2)nCONHR′中的一个,两个,三个或四个基团取代,其中n和R′是如前面所确定的,限制条件是当Ar是吩噻嗪时,Sp1是一个仅与氮连接的键;
Sp2是一个键,-S-,或-O-,限制条件是当Alk2是一个键时,Sp2是一个键;
Z1是H,(C1-C5)烷基或苯基,它可任意被(C1-C5)烷基,(C1-C5)烷氧基,(C1-C4)疏代烷氧基,卤素,硝基,-COOR′,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,-O(CH2)nCONHR′,或-S(CH2)nCONHR′中的一个,两个或三个基团取代,其中n和R′是如前面所确定的;
Sp是直链或支链的二价或三价(C1-C18)基团,二价或三价芳基或杂芳基基团,二价或三价(C3-C18)的环烷基或杂环烷基基团,二价或三价的芳基-芳基或杂芳基-芳基(C1-C18)基团,二价或三价的环烷基-烷基或杂环烷基-烷基(C1-C18)基团或二价或三价(C2-C18)不饱和烷基基团,其中杂芳基最好是呋喃基,噻嗯基,N-甲基吡咯基,吡啶基(pyridinyl),N-甲基咪唑基,噁唑基,嘧啶基,喹啉基,异喹啉基,N-甲基咔唑基,氨基香豆素基或吩嗪基,其中如果Sp是三价基团,Sp还可被低碳(C1-C5)二烷基氨基,低碳(C1-C5)烷氧基,羟基,或低碳(C1-C5)硫代烷基基团替代;和
Q是=NHNCO-,=NHNCS-,=NHNCONH-,=NHNCSNH-,或=NHO-。
其中较佳的是,Alk1是有支链或无支链(C1-C10)亚烷基链;Sp1是一个键,-S-,-O-,-CONH-,-NHCO-或-NR′,其中R′如前面所确定的,限制条件是当Alk1是一个键时,Sp1是一个键;
Ar是1,2-,1,3-,或1,4-亚苯基,它可任意被(C1-C6)烷基,(C1-C5)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,-O(CH2)nCONHR′,或-S(CH2)nCONHR′中的一个,两个或三个基团取代,其中n和R′是如前面所确定的,或Ar为1,2-,1,3-,1,4-,1,5-,1,6-.1,7-,1,8-,2,3-,2,6-,或2,7-亚萘基,每个亚萘基可任意被(C1-C6)烷基,(C1-C5)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,-O(CH2)nCONHR′,或-S(CH2)nCONHR′中的一个,两个,三个或四个基团取代;
Z1是(C1-C5)烷基或苯基,它可任意被(C1-C5)烷基,(C1-C4)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,-O(CH2)nCONHR′,或-S(CH2)nCONHR′中的一个,两个或三个基团取代;
Alk2和Sp2同为一个键;和
Sp和Q如上面贴近部份所确定的。
卡利许霉素可以和如抗体上的赖氨酸残基连接。在美国专利No.5,053,394中公开的与赖氨酸的连接产生了在通常生理条件下对水解稳定的共轭物。
美国专利No.5,053,394也公开了一种共轭物一种亲核卡利许霉素衍生物,如酰肼,其可在弱酸性条件下与抗体上的高碘酸氧化的碳水化合物反应。这产生了一种席夫碱或其衍生物,如腙,如果需要它还可用如氰基氢硼化物还原以生成对水解稳定的共轭物。
欧洲专利申请号No.0689845公开了可与从卡利许霉素获得的亲核衍生物,特别是酰肼和相关的亲核试剂一起使用的其他连接剂。这些连接剂在一些场合(如,P67.6)下是有用的,当在药物和连接剂间的连接键可以水解时,可获得较好的活性。这些连接剂有两种官能团。一种基团通常是用于和载体反应的羧酸。当酸基团被适当激活后,它可与载体上的一个自由的氨基,如单克隆抗体载体的赖氨酸侧链上的氨基形成一个酰胺键。另一种官能团通常是羰基即醛基或酮基,它可与经适当修饰的治疗试剂反应。羰基基团可与药物上的酰肼基团反应生成一个腙键。该键在靶细胞上可水解释放共轭物中的治疗试剂。
本发明采用的最佳的双重官能团连接剂是4-(4-乙酰基苯氧基)丁酸(AcBut),它可形成一个较佳的产物,其中共轭物(包括γ卡利许霉素或N-乙酰基γ卡利许霉素)通过与3-巯基-3-甲基丁酸酰肼,连接剂4-(4-乙酰基苯氧基)丁酸(AcBut)和人或人化的单克隆抗体靶载体反应而官能化。
单体共轭物
卡利许霉素的天然疏水性质使得在制备有医疗应用所必需的高药物负荷量和合理得率的单体共轭物的过程中产生了困难。连接剂如在欧洲专利申请号No.0689845中公开的AcBut连接剂增加了连接键的疏水性,并增加了治疗试剂和单克隆抗体(MoAb)间的共价间距,从而恶化了这个问题。
由于卡利许霉素的天然疏水性质,在较高的药物负荷量时产生了卡利许霉素/载体共轭物的凝集。为获得合理的单体产物量就必须限制药物负荷量。在一些情况下,如在欧洲专利申请号No.0689845中公开的共轭物,由于过度的凝集,因此采用美国专利No.5,053,394所公开条件的反应条件不能制成可用得率的有用于治疗用途的负荷量的共轭物。这些反应条件在共轭反应中用DMF作为助溶剂。因此需要有一种能有较高负荷量/得率而无凝集和无物质固有损失的方法。
人化载体包括(但不局限于)蛋白质,如这里用于寻靶胞毒治疗试剂的人或人化的单克隆抗体,如P67.6和其它在这里公开的人化单克隆抗体,对于这些人化载体采用一种非亲核,蛋白质相容的缓冲液可生成有较高药物负荷量/得率和减少凝集并有很好活性的单体卡利许霉素衍生物/载体共轭物,其中缓冲液含有(i)助溶剂丙二醇(PG)和(ii)至少包括一个C6-C18的羧酸的添加剂。较佳的酸为C7-C12酸,最佳的酸是辛酸(CA)。对于从OSu酯或其它比较活化的酯制备的共轭物的较佳的缓冲液是磷酸盐缓冲液(PBS)或N-2-羟乙基派嗪-N′-2-乙烷磺酸(Hepes缓冲液),而对于从抗体的氧化碳水化合物制备的共轭物的较佳的缓冲液是乙酸钠。这些共轭反应所用的缓冲液不能含游离的氨基或亲核试剂。对于其它类型的共轭物的可接受的缓冲液可由该领域技术人员预先确定。或者,采用非亲核,蛋白质相容的含有叔丁醇而不含添加剂的缓冲液也可产生有较高药物负荷量/得率和减少凝集的单体卡利许霉素衍生物/载体。
所用助溶剂的量是单体共轭有效量,其可由该领域技术人员不预先做试验即可确定。添加剂的量是单体共轭物加强有效量。其也可由该领域技术人员不预先做试验即可确定。丙二醇(PG)加入量为总溶液体积的约10%至约60%,较佳的为约10%至约40%,最佳的为约30%,添加剂至少包括一个C6-C18的羧酸,较佳的为辛酸,其用量为约20mM至约100mM,较佳的为约40mM至约90mM,最佳的为约60mM*,添加剂加入共轭反应以产生有较高药物负荷量/得率和减少量凝集的单体卡利许霉素衍生物/载体。一些或所有的PG助溶剂用于将药物转移入共轭混合物中。当用于转移药物的助溶剂占共轭混合物总体积的10%或更少时,它可任意被乙醇或DMSO代替。
或者,C6-C18羧酸,较佳的为辛酸的浓度可增加至150-300mM,助溶剂降低至含1-10%的丙二醇,乙醇或DMSO,其较佳的为200mM辛酸和5%的丙二醇或乙醇。
另外,在共轭反应中可加入总溶液体积的约10%至约25%,最好为约15%的叔丁醇,以产生有较高药物负荷量/导率和减少量凝集的单体卡利许霉素衍生物/载体。
在前面的反应中,MoAb的浓度为约1至约15mg/ml,药物即AcBut卡利许霉素的浓度为约0.025至约1mg/ml。反应在PBS或醋酸缓冲液中进行,pH为约4.0至约8.5(它与制备的共轭物的类型有关),温度为约室温(25℃)至约37℃,反应时间从15分钟至24小时。共轭物可用常规方法例如HPLC,FPLC或SEPHACRYL S-200TM回收纯化,纯化过的共轭物是单体形式的,它含有约2至约6摩尔/摩尔药物/MoAb、
助溶剂和/或添加剂的加入可改变缓冲液的pH值,因此需要调节溶液的pH至较佳的约4.0至8.5的pH范围。含有助溶剂和添加剂的缓冲液对于从OSu酯制备的共轭物的较佳pH值为7.0至8.5,或对于从抗体的氧化的碳水化合物制备的共轭物约为4.0至6.5。最佳的是,含有助溶剂和添加剂的缓冲液对于从OSu酯制备的共轭物的较佳pH值为7.7,或对于从抗体的氧化的碳水化合物制备的共轭物约为5.5。其它类型的共轭物的可接受的pH范围可很容易被该领域技术人员所确定。
对于各种鼠型单克隆抗体,采用含前述添加剂的其它组合可提高药物负荷量和单体共轭物的得率,应当理解任何具体的蛋白质载体对确切条件或添加剂的选择需要作些改动以达到最佳的效果。
较佳实施例的具体描述
本发明在下面还描述了具体的工作实施例,它用于进一步描述本发明而无限制意义。
实施例1
在DMF中的共轭反应:采用不同的DMF浓度,药物/蛋白质比例和缓冲液。
第一组是用不同的DMF浓度,药物/蛋白质比例和缓冲液对鼠和人的P67.6上的N-乙酰基γ卡利许霉素进行试验,其中N-乙酰基γ卡利许霉素通过3-巯基-3-甲基丁酸酰肼连接在连接剂4-(4-乙酰基苯氧基)丁酸上的反应而官能化并以OSc酯激活(这里称为AcBut卡利许霉素)。结果说明当药物负荷量为1.5-3摩尔药物/摩尔蛋白质时,由于物质凝集而有损失,这些“标准”的条件只产生得率20-30%的单体共轭物,因此需要改变条件。
在含4.5-5mg/mL蛋白质的PBS缓冲液的蛋白质溶液(50mM磷酸钠,100mMNaCl,pH7.4)中加入含6摩尔当量药物的DMF溶液(3.3mg/ml),并再加入DMF至最后浓度为25%。将它在室温下轻微搅拌并培育过夜。然后对体积小于0.5mL用FPLC SuperoseTM或大体积用SEPHACRYL S-200TM以纯化共轭的蛋白质。
对于mP67.6(大批量),结果在药物负荷量为1.9M/M时仅有32%的单体蛋白质得率。对于hP67.6,单体蛋白质得率在药物负荷量为2.9M/M时为26%。因此,尽管单体药物负荷量是可接受的,但是纯化困难及由于凝集而有物质损失所导致的低得率被认为不能用来进一步开发和放大。
进行一次药物负荷量对30%DMF内单体得率比较试验,用hP67.6中的pH7.4PBS中溶液以及各种当量(5-9.5M/M)的药物。所有的样品在室温下培育过夜,在PD10柱上用PBS交换,并用分光光度计分析蛋白质得率和药物负荷量。然后样品还用ZorbaxTMGF-250,在0.2M,pH7磷酸钠,及pH7.4用PBS中的SuperoseTM进行HPLC分析。然后在PBS中用FPLC SuperoseTM进行纯化。结果是:可获得的最大负荷量是3-3.5M/M,但得率相当低(<20%)。
如上所述进行类似的负荷量测定,只是用Hepes缓冲液(100mM,pH7)代替PBS缓冲液。结果是:除了在柱上有凝集物沉淀析出或粘着外并无其它不同,因此在最后纯化中没有发现有凝集物。然后如上进行负荷量研究,但是在缓冲液中加入0.5M NaClO4。它用作药物的可能的增溶剂。结果是:没有明显的优点。
然后在Hepes缓冲液(50mM,pH7.4)中而不是PBS中进行一个附加的研究。结果是:无明显优点。
实施例2
人化抗体的优化试验
解离凝集物的实验
在这方面还没有发现比最初的方法有所改进。研究了导致凝集量减少的条件或许可增加药物负荷量和/或纯化单体更高的得率的可能性。所有迹象表明凝集的共轭物是可能由于疏水作用而非共价缔合的,假定研究它们的性质是有启发的。因此首先进行试验寻找可破坏已形成的凝集物的添加剂。假定任何具有这种活性的物质如果用于共轭反应时也可防止凝集(从而增加单体的得率)。所用试剂的选择根据是FDA已认可它们用作药物添加剂的安全性,它们使疏水物质增溶的有效性和/或它们与蛋白质的相容性。通过这些研究鉴定出三种有效的添加剂。
不同的添加剂的十二种排列变换被用来排除凝集。将hP67.6-AcBut卡利许霉素共轭纯化反应获得的含有~25%二聚物被的凝集物浓缩至0.7mg/ml蛋白质。在富含二聚物的hP67.6AcBut中加入等分的各种添加剂:PBS,0.3M甘氨酸,0.2M甘氨酸+2%麦芽糖,0.1M甘氨酸+0.1M组氨酸,1%Pluronic F-68,80mM辛酸,40mM辛酸+6mM N-乙酰基-色氨酸,1%苯甲醇,0.5%苯甲酸钠,33%丙二醇,和25%甘油。每份处理的等份在室温下培育过夜,然后用ZorbaxTMGF-250和SuperoseTM 12用双检测器在280和333nm进行凝胶过滤HPLC分析。对于凝集物(或二聚物)对单体的比例和总的单体得率都进行分析。结果是:丙二醇(PG),辛酸(CA)和甘油在减少二聚物而不减少蛋白质得率方面比其它添加剂好。它们可减少凝集物50-90%而其它添加剂基本上无影响。
实施例3
采用无凝集的添加剂的共轭反应
根据这些结果,在共轭反应中采用PG,CA和甘油。此外,还试验了异丙醇和叔丁醇。异丙醇和叔丁醇曾以低百分含量用作蛋白质的助溶剂而对蛋白质没有明显危害(个人观察)。
在25%PG,80mM CA,25%甘油,25%异丙醇(IPA),25%叔丁醇,或25%PG+80mM CA存在时进行hP67.6与AcBut-卡利许霉素的共轭反应。所有反应均在含3.25mg/ml蛋白质(最终浓度)的PBS,pH7.4,6摩尔药物/摩尔MoAb中进行。所有反应与在25%DMF中进行的对照共轭反应比较,然而所有的测试溶液含有来自药物原料的~5%DMF。在25%PG或25%DMF中也进行4M/M药物的共轭反应以作对照。所有的样品在室温下培育过夜,在PD10柱上用PBS交换,并用分光光度计分析蛋白质得率和药物负荷量。然后样品还在ZorbaxTM和SuperoseTM上进行HPLC分析。在共轭反应后,共轭物在FPLC SuperoseTM上纯化。结果是:除甘油(低负荷量)外,所有的这些添加剂都是有利的。在共轭物得率,药物负荷量和减少凝集方面PG+CA是最佳的。
因此,下面进行一系列的CA和其它添加剂的组合的研究,PG浓度的优化和与叔丁醇直接比较。
如上所述由于PG中加入CA看上去提高了蛋白质得率,药物负荷量并减少了凝集,因此对hP67.6用PG,叔丁醇或异丙醇(均为25%),及有或没有CA(80mM)进行共轭反应以观察CA是否能与其它添加剂协同加强作用。反应条件和分析方法如上,结果是:叔丁醇和CA在这些条件下是不相容的,而异丙醇在提高得率和减少凝集方面没有PG的效果好。
当所用PG为10,15或20%及CA是40或80mM时,进行共轭反应以优化PG+CA的反应条件。分析方法如上。结果是:20%PG和80mM的效果最佳,其形成3-3.8的负荷量,得率大于60%。结论:叔丁醇可有效地代替PG/CA,因此还要进行试验以确证这个结论并优化用叔丁醇时的条件。
对PBS中的hP67.6用5-20%的叔丁醇和6-10当量的药物进行共轭反应。结果是:10%的叔丁醇对于6当量的药物是足够的,产生的共轭物的负荷量为2.3M/M,在粗制产品中稍微有些凝集物。而用Hepes缓冲液代替PBS显示没有优点。
用20%丙二醇(PG)和80mM辛酸(CA)与15%叔丁醇进行共轭反应。每个样品用PBS中的6,9和12摩尔药物/摩尔hP67.6来测试。结果是:PG+CA的组合看上去更好,它以蛋白质得率表达有较高的负荷量,但是两种方法在负荷量降低时其得率几相同。
在这一点上,20%PG和80mM CA与15%叔丁醇相比是较佳的添加剂,但是两者均比原来的反应条件有了显著的改进。然而,叔丁醇对PBS中的蛋白质的pH无影响,而PG使pH从7.4降低至~6.9。这与下列观察有关,即叔丁醇的反应在1-3小时内结束,而PG/CA的反应需要过夜。
实施例4
用PG/CA,不同的pH进行共轭反应
在30%RG/80mM CA中进行一系列共轭反应但调节和不调节pH至7.4。同样,在无DMF下用25%至30%的叔丁醇进行共轭反应。结果是:pH的调节可更好地形成药物的掺入。
很明显,与在叔丁醇中的共轭反应相比,当pH重新调节至7.4时,PG+CA在形成有高负荷量的共轭物时其得率要高的多。对于~2M/M的负荷量来说,两种方法有相近的得率,但当在共轭反应中增加药物/蛋白质比例而增加负荷量(如负荷量为5M/M)时,用叔丁醇的反应的得率显著地降低至只有用PG/CA获得的的得率25%。
实施例5
大批量制备
现在进行大批量制备(用20-24mg蛋白质而不是试验规模的每个样品用0.5-1mg)。其目的是测定新的反应条件在规模放大时的适用性,以及在一定范围的药物载荷时制备共轭物。这些共轭物在体内对异种移植肿瘤进行测试以确证添加剂可产生有效的共轭物,且较高负荷量的共轭物比较低负荷量的共轭物更有效。
用仅4摩尔当量的药物和20%PG/80mM CA,5%DMF对hP67.6-AcBut进行大批量制备(用了30mg蛋白质),pH调节至7.5。在这些条件下,形成的凝集物比原来的制备物要少的多。最终纯化的单体有1.9M/M药物,蛋白质得率为67%。
为获得较高的药物负荷量,进行同样的条件,只是共轭反应用9当量药物代替6当量药物。这只导致稍微高一点的凝集量,但是获得的单体共轭物的药物负荷量为3.2M/M,蛋白质当量只稍降低至~60%。
尽管大批量(30mg蛋白质)的制备比原来的结果提高很多,但是其仍比根据小批量的试验所预计的负荷量要低30-40%。现在怀疑是大批量试验中稍微增加的DMF引起了这个问题。因此,进行了许多小批量的对一定浓度范围的DMF的研究以证明这一点。
实施例6
共轭反应过程中少量的DMF的影响
在10%叔丁醇中,以4M/M药物,而DMF浓度分别为1%至7%进行共轭反应。这里药物原料储备液为10mg/ml DMF以使在共轭反应时有低的DMF浓度。结果是:DMF浓度增高将降低药物的结合。
用6.4M/M药物和30%PG/80mM CA进行小批量共轭反应,只是用0至8%的DMF对25%叔丁醇以及2%至8%的DMF比较。药物原料储备液用PG制备以更准确地控制DMF的浓度,结果是:在PG/CA和叔丁醇中DMF均增加了凝集(从而降低了单体得率),且在PG/CA中的增加程度更大,因此再次发现PG/CA比叔丁醇的共轭反应要好。
不用DMF进行大批量的制备以证明小批量反应的结果。用30%PG/80mMCA和6.1M/M药物进行共轭反应。测试每等份,等份显示如同根据小批量所预计的那样,这些条件产生3.2M/M的负荷量,这证明应避免用DMF作为助溶剂。
再增加3当量药物进行这一共轭反应,它形成一个药物负荷量为4.4M/M的最终纯化单体,蛋白质得率为46%。
因此完成了三批大批量的制备,生成了药物负荷量为1.9,3.2和4.4摩尔药物/摩尔蛋白质的共轭物。对这些在体内和体外进行评估。PG和CA的组合是最佳的反应添加剂,DMF对反应不利。
实施例7
最终的优化
进行一系列的测试以确定最终的最优PG和CA浓度,最优的pH,加入的顺序和作为药物助溶剂的DMF替代物。
在30%PG/80mM CA中进行小批量共轭反应,只是加入MoAb,PG,CA和在PG,EtOH或DMSO中制备的药物原料储备液的顺序不同。结果是:最佳的加入顺序为MoAb,然后是PG,然后是CA(调节pH),然后是在PG中制备的药物原料储备液。EtOH和DMSO也可用来代替药物原料储备液中的PG。
用40,55,75,和80mM CA,均与25%PG进行共轭反应的研究。结果是:发现55mM CA在蛋白质得率和药物负荷量方面的效果最佳。
用40,50,60和70mM CA均与25%PG进行另一组共轭反应研究。结果是:发现60mM CA在蛋白质得率和药物负荷量方面的效果最佳。
用25%PG+80mM CA和0,2或4%DMF进行共轭反应研究。这用来观察低水平的DMF是否有害。结果是:没有很大差别,因此只有当其浓度大于4%时才成问题。
在共轭反应中采用不同速度的搅拌来进行共轭反应。结果是:没有差别。
将药物加入EtOH而不是PG中来进行共轭反应。结果是:与用PG中的药物相比没有显著变化。
用PG/CA和6M/M药物进行一系列共轭反应,只是变换pH从7.0至8.5值。通过检测反应物和水解产物(用RP-HPLC)来检测反应的进程和负荷量的水平。结果是:所有的试验显示pH越高,反应越快,其范围从在pH7时的12小时至pH8.5时的小于45分钟。因此可断定pH大于7.5时形成了最高的得率和负荷量。
用PG/CA添加剂利用同样的步骤进行AcBut卡利许霉素和其它两个人化的MoAb,CT-M-01和A33的共轭反应。对于这些人化的MoAb可获得与用人化的P67.6小批量和大批量生产相近的负荷量和得率。
实施例8
AcBut卡利许霉素与5mg的人化的CT-M-01单克隆抗体在25%丙二醇(PG)和80%辛酸存在时进行共轭反应。反应在室温下(25℃)反应过夜(约24小时)。产物用HPLC分析。
结果是:药物负荷量为1.9M/M的有75%单体。
实施例9
AcBut卡利许霉素与36.6mg的人化的hCT-M-01单克隆抗体在30%PG和60mM CA存在时进行共轭反应。反应在约25℃下反应2小时。产物用HPLC分析。
结果是:药物负荷量为2.2M/M的有60%单体。
实施例10
AcBut卡利许霉素与1mg的人化的A33 MoAb在30%PG和60mM CA存在时进行共轭反应。
结果是:约有50%的药物负荷量为1.8M/M的单体得率。过去的试验显示由于hA33的共轭物有显著的凝集趋势,因此它是一种难以处理的蛋白质。
实施例11
AcBut卡利许霉素与50mg的hP67在200mM CA和5%乙醇(来自药物原料储备液)存在时进行共轭反应。在25℃下培育2小时。
结果是:有~95%的药物负荷量为2.1M/M的单体,蛋白质得率为65%。
发现当CA浓度显著增加且助溶剂减少时,可获得很好的结果。
实施例12
人化抗体的最终的过程
根据上面所有的结果,最终采用的将hP67.6与AcBut-卡利许霉素共轭的步骤推荐如下:采用五种原料储备液液:PBS(50mM磷酸钠,100mM NaCl,pH7.4)中的~6.5mg/ml的hP67.6,丙二醇(PG),1M NaOH,pH7.4的PBS中的1M辛酸(CA),和PG中的药物(~6mg/ml)。在共轭反应中最终的浓度为:30%PG(5%的PG来自药物原料储备液),60mM CA,约4mg/ml的p67.6,和6摩尔药物/摩尔hP67.6。在hP67.6中加入PG并充分混合。加入CA并充分混合。或者加入CA至最终浓度为200mM,并通过加入药物(AcBut卡利许霉素)获得5%PG(或EtOH)。通过加入~10mlNaOH/ml溶液调节pH至7.7-7.8,然后加入药物并剧烈混合溶液。溶液在25℃下振荡培育3小时,然后通过Millex过滤器过滤以除去不溶物。然后纯化共轭物在PBS(pH7.4)的SEPHACRYL S-200TM用不超过~1%的负荷量凝胶过滤或,对于少量的小于0.5ml的共轭反应用PBS中的SuperoseTM12FPLC进行凝胶过滤。最终形成的单体(小于4%)共轭物蛋白质得率大于60%,药物负荷量大于2.5摩尔药物/摩尔蛋白质。
该过程对于三种测试的人化的MoAB,A33,CT-M-01和P67.6是有效的,它们分别是两种不同的同型异种(分别为IgG1,IgG4和IgG4)。
实施例13
鼠型抗体反应条件的优化
当用鼠型MoAB时采用同样的步骤,通过下面的实施例可发现,它比只用DMF作为助溶剂要有所改进,但是与人化抗体相比阻止凝集的效果一般较差。该结果对于不同的MoAb差别较大,这再一次说明对于不同的卡利许霉素/载体共轭物最佳的共轭反应步骤是不同的,但是本发明中各种常用过程在所有测试例中与只用DMF作为助溶剂获得的结果相比均有显著的提高。
用PG/CA进行共轭反应的上述的步骤生成了下列负荷量:
MoAb 负荷量(M/M)
Anti-Tac 0.7
M5/114 1.2
Campath II 1.4
MN-1 1.2
LC-1 1.0
LK-26 1.2
TH-69 1.0
A33 1.1
蛋白质得率是适中的,在20至40%之间。当mA33与8M/M药物进行共轭反应时,单体的最终负荷量只有1.1-1.3M/M。由于叔丁醇是最佳的备用添加剂,因此负荷量为0.7m/M的anti-Tac共轭物在20%叔丁醇存在时再进行共轭反应。这增加了负荷量至2.0M/M,但是得率只有23%。
用PG+叔丁醇进行共轭反应
尽管PG/CA系统对于上述的MoAb只有较少提高,但叔丁醇/(t-Bu/PG)PG看上去是有希望的。下面的研究描述了用PG和叔丁醇的组合的共轭反应。这可得出结论PG/叔丁醇系统更适用于鼠型MoAb,而PG/CA更适用于所试的人化的MoAb。
用各种叔丁醇和PG浓度进行共轭反应。发现对于多种鼠型MoAb在AcBut卡利许霉素和叔丁醇存在时PG有助于使共轭反应溶液增溶(澄清)。当anti-Tac和20%叔丁醇,10%PG,和6M/M药物进行共轭反应时,最终的单体的药物负荷量为1.3M/M,得率为40%。当其和15%叔丁醇,15%PG,和6.7M/M药物进行共轭反应时,产物的药物负荷量为1.4M/M,得率为50%,其比前一个例子稍有提高,但是比在PG/CA中获得的0.7M/M负荷量和~20%得率要高的多。当采用相同条件,只是蛋白质浓度从~2增加至2.8mg/ml,最终的药物负荷量提高至2.2M/M。
对于mA33,它通常是一个难以处理的蛋白质,没有发现有可使其负荷量明显高于1.0M/M的反应条件,但是上述的叔丁醇和PG(和8M/M药物)的组合甚至在大批量生产中都可形成60%得率的共轭物。三种IgG1鼠型MoAb(假定其有相近的化学活性)MOPC,M44和M67,在基本相同的条件(15%叔丁醇,10-20%PG,6.7M/M药物)下进行共轭反应时,它们均形成负荷量为~1.0但得率在14-45%的单体。对于MOPC,将蛋白质浓度增加至2.8M/M(和anti-Tac一样)并用15%叔丁醇,20%PG缓冲液系统及8M/M药物时,可使药物负荷量增加至1.7M/M,得率至~50%。
鼠型抗体的最终的步骤
根据这一系列的共轭反应,对这些鼠型MoAb建议采用的步骤基本上与测试过的人化的MoAb的步骤不同。此外,对于测试过的不同的鼠型MoAb中获得的优化的蛋白质得率和药物负荷量有相当大的不同,这表示对于任何具体的蛋白质载体,需要有某种优化条件的方法以发现一种最佳的条件。
用pH7.4的PBS作为缓冲液,但是MoAb原料在4至5.5mg/ml。用叔丁醇作为附加的助溶剂,但是不用CA。药物原料(8-10mg/ml)制备在DMSO或DMF中。最终的反应条件是15%叔丁醇,~20%丙二醇(若要使溶液澄清则需更多),2-4%DMSO(来自药物原料)和6-8摩尔药物/摩尔蛋白质。共轭反应在25℃下振荡培育3至20小时。纯化步骤如上述对人化的共轭物一样。最终蛋白质得率在25%至60%之间,药物负荷量根据具体的MoAb为1至2.2摩尔药物/摩尔MoAb。
实施例14
叔丁醇对于碳水化合物共轭物的作用
MOPC-21在pH5.5醋酸盐缓冲液中用15mM NaIO4在室温下氧化45分钟。然后缓冲液用新鲜的醋酸盐缓冲液替换以除去用过的氧化试剂。一部分氧化过的这种抗体用通过N-乙酰基γ-卡利许霉素与3-巯基-3-甲基丁酸(GAD)酰肼在15%DMF下反应生成的二硫化物来处理。第二部分用相同浓度的GAD在5%DMF和15%叔丁醇处理。两个反应均在室温下反应17小时。然后每个反应均将缓冲液改为pH7.4的PBS。用叔丁醇的共轭反应的凝集量比只用DMF的反应的凝集量要少(4.1%对7.3%)。用凝胶排阻色层分析纯化后,只用DMF反应的共轭物的负荷量为3.2M/M,有3%的残留凝集,而当叔丁醇存在时制备的共轭物的负荷量为5.1M/M,并且检测不到有残留凝集。
实施例15
PG/CA对于非水解性共轭物形成的影响
h-CT-M-01用二硫化物的OSu酯处理,其中二硫化物通过N-乙酰基γ-卡利许霉素和4-巯基-4-甲基戊酸在含15%DMF的Hepes缓冲液中反应产生。第二个共轭反应在30%PG和80mM CA而不是DMF中进行。两个反应均在室温下反应2小时。然后每个反应均将缓冲液改为pH7.4的PBS。尽管两个反应的凝集量(~2%)和负荷量(用DMF的3.95M/M相对于用PG+CA的4.12M/M)相当,但是在PG+CA存在时反应测得的得率更高(60%对50%)。
所述的所有专利,申请,论文,文献出版物和测试方法在这里均加上参改文献。
该领域技术人员可根据上述细节描述对本发明作各种变化。因此这类明显的变化均包括在附加的权利要求所完全认定的范围内。
Claims (34)
1.一种制备有较高药物负荷量/得率和减少凝集量的单体卡利许霉素衍生物/载体共轭物的方法,共轭物有化学式
Pr(-X-S-S-W)m
其中:
Pr为一种蛋白质载体,
X是一种连接剂,它包括有任何可与蛋白质载体反应的活性反应基团的产物,
W是通过除去天然存在的甲基三硫化物基团后形成的卡利许霉素基团;m是0.5至15的数,
所述方法包括步骤:
(1)使卡利许霉素衍生物和蛋白质载体在一个非亲核的,蛋白质相容的,pH范围约为4.0至8.5的缓冲液中培育,溶液还包括(a)一种选自丙二醇,乙醇,DMSO,及其组合的助溶剂,和(b)一种至少包括一个C6-C18羧酸的添加剂,其中培育在约25℃至约37℃进行约15分钟至约24小时;和
(2)纯化步骤(1)生成的共轭物以生产单体共轭物。
2.根据权利要求1所述的方法,其中X有化学式Z-Sp,其中:
Sp是直链或支链的二价或三价(C1-C18)基团,二价或三价芳基或杂芳基团,二价或三价(C3-C18)的环烷基或杂环烷基基团,二价或三价的芳基-芳基或杂芳基-芳基(C1-C18)基团,二价或三价的环烷基-烷基或杂环烷基-烷基(C1-C18)基团或二价或三价(C2-C18)不饱和烷基基团,其中杂芳基最好是呋喃基,噻嗯基,N-甲基吡咯基,吡啶基,N-甲基咪唑基,噁唑基,嘧啶基,喹啉基,异喹啉基,N-甲基咔唑基,氨基香豆素基,或吩嗪基和其中如果Sp是三价基团,Sp还可被低碳(C1-C5)二烷基氨基,低碳(C1-C5)烷氧基,羟基,或低碳(C1-C5)硫代烷基基团替代;和
3.根据权利要求1所述的方法,其中X有化学式
(CO-Alk1-Sp1-Ar-Sp2-Alk2-C(Z1)=Q-Sp)
其中
Alk1和Alk2各自代表一个键或有支链或无支链的(C1-C10)的亚烷基链;
Sp1是一个键,-S-,-O-,-CONH-,-NHCO-,-NR′-,-N(CH2CH2)2N-,或-X-Ar′-Y-(CH2)n-Z其中X,Y,和Z各自为一个键,-NR′-,-S-或-O-,限制条件是当n=0时,Y和Z中的至少一个须是一个键,且Ar′是1,2-,1,3-,或1,4-亚苯基,它可任意被(C1-C5)烷基,(C1-C4)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,-O(CH2)nCONHR′,或-S(CH2)nCONHR′中的一个,两个或三个基团取代,限制条件是当Alk1是一个键时,Sp1是一个键;
n是0至5间的整数;
R′是有支链或无支链的(C1-C5)链,它可任意被-OH,(C1-C4)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,(C1-C3)二烷基氨基,或(C1-C3)三烷基铵-A-中的一个或两个基团取代,其中A-是药物学上可接受的成盐阴离子;
Ar是1,2-,1,3-,或1,4-亚苯基,它可任意被(C1-C6)烷基,(C1-C5)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,-O(CH2)nCONHR′,或-S(CH2)nCONHR′中的一个,两个或三个基团取代,其中n和R′是如上述所确定的,或Ar为1,2-,1,3-,1,4-,1,5-,1,6-,1,7-,1,8-,2,3-,2,6-,或2,7-亚萘基或每个亚萘基或吩噻嗪可任意被(C1-C6)烷基,(C1-C5)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′-,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,或-S(CH2)nCONHR′中的一个,两个,三个或四个基团取代,其中n和R′是如上述所确定的,限制条件是当Ar是吩噻嗪时,Sp1是一个仅与氮连接的键;
Sp2是一个键-S-,或-O-,限制条件是当Alk2是一个键时,Sp2是一个键;
Z1是H,(C1-C5)烷基或苯基,它可任意被(C1-C5)烷基,(C1-C5)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,-O(CH2)nCONHR′,或-S(CH2)nCONHR′中的一个,两个或三个基团取代,其中n和R′是如上;
Sp是直链或支链的二价或三价(C1-C18)基团,二价或三价芳基或杂芳基基团,二价或三价(C3-C18)的环烷基或杂环烷基基团,二价或三价的芳基-芳基或杂芳基-芳基(C1-C18)基团,二价或三价的环烷基-烷基或杂环烷基-烷基(C1-C18)基团或二价或三价(C2-C18)不饱和烷基基团,其中杂芳基最好是呋喃基,噻嗯基,N-甲基吡咯基,吡啶基,N-甲基咪唑基,噁唑基,嘧啶基,喹啉基,异喹啉基,N-甲基咔唑基,氨基香豆素基或吩嗪基,其中如果Sp是三价基团,Sp还可被低碳(C1-C5)二烷基氨基,低碳(C1-C5)烷氧基,羟基,或低碳(C1-C5)硫代烷基基团替代;和
Q是=NHNCO-,=NHNCS-,=NHNCONH-,=NHNCSNH-,或=NHO-。
4.根据权利要求3所述的方法,其中
Sp是一个键,-S-,-O-,-CONH-,-NHCO-或-NR′,其中n和R′如权利要求3所确定的,限制条件是当Alk1是一个键时,Sp1是一个键;
Ar是1,2-,1,3-,或1,4-亚苯基,它可任意被(C1-C6)烷基,(C1-C5)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,-O(CH2)nCONHR′,或-S(CH2)nCONHR′中的一个,两个或三个基团取代,其中n和R′是如权利要求3所确定的,或Ar为1,2-,1,3-,1,4-,1,5-,1,6-,1,7-,1,8-,2,3-,2,6-,或2,7-亚萘基,每个亚萘基可任意被(C1-C6)烷基,(C1-C5)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,-O(CH2)nCONHR′,或-S(CH2)nCONHR′中的一个,两个,三个或四个基团取代;
Alk1是有支链或无支链(C1-C10)亚烷基链;
Z1是(C1-C5)烷基或苯基,它可任意被(C1-C5)烷基,(C1-C4)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,-O(CH2)nCONHR′,或-S(CH2)nCONHR′中的一个,两个或三个基团取代;和
Alk2和Sp2同为一个键。
5.根据权利要求4所述的方法,其中Sp1为-O-,Alk1为C3亚烷基,Ar是1,4-亚苯基,和Z1是C1烷基。
6.根据权利要求3所述的方法,其中Q是=NHNCO-和Sp是-CH2C(CH3)2-。
7.根据权利要求2所述的方法,其中Z是-NHC(=O)-和Sp是-CH2CH2C(CH3)2-。
8.根据权利要求2所述的方法,其中Z是-CH=NNHC(=O)-和Sp是-CH2C(CH3)2-。
9.根据权利要求1所述的方法,其中卡利许霉素衍生物包括一种γ卡利许霉素或一种N-乙酰基γ卡利许霉素衍生物。
10.根据权利要求9所述的方法,其中卡利许霉素衍生物在步骤(1)中含量为约0.025mg/ml至约1.0mg/ml。
11.根据权利要求1所述的方法,其中蛋白质载体包括一种人化的单克隆抗体。
12.根据权利要求11所述的方法,其中人化的单克隆抗体在步骤(1)中的含量为约1mg/ml至约15mg/ml。
13.根据权利要求1所述的方法,其中步骤(1)中的添加剂的量为20至300mM。
14.根据权利要求1所述的方法,其中助溶剂包括丙二醇,其含量为溶液体积的约10%至约60%。
15.根据权利要求1所述的方法,其中步骤(1)中的添加剂包括辛酸,其含量为约20mM至约100mM。
16.根据权利要求1所述的方法,其中步骤(1)中的助溶剂是丙二醇,其含量为溶液体积的30%,步骤(1)中的添加剂包括辛酸,其含量为60mM。
17.根据权利要求1所述的方法,其中步骤(1)中的助溶剂含量为溶液体积的xq1%至xq10%,步骤(1)中的添加剂包括辛酸,其含量为约150mM至约300mM。
18.根据权利要求17所述的方法,其中助溶剂是乙醇。
19.根据权利要求18所述的方法,其中乙醇在步骤(1)中的含量为溶液体积的5%,步骤(1)中的添加剂辛酸的含量为200mM。
20.根据权利要求17所述的方法,其中步骤(1)中的助溶剂为丙二醇,其含量为溶液体积的5%,步骤(1)中的添加剂辛酸的含量为200mM。
21.一种制备有较高药物负荷量/得率和减少凝集量的单体卡利许霉素衍生物/载体共轭物的方法,共轭物有化学式
Pr(-X-S-S-W)m
其中:
Pr为一种蛋白质载体,
X是一种连接剂,它包括有任何可与蛋白质载体反应的活性反应基团的产物,
W是通过除去天然存在的甲基三硫化物基团后形成的卡利许霉素基团;m是0.5至15间的数,
所述方法包括步骤:
(1)使卡利许霉素衍生物和蛋白质载体在一个非亲核的,蛋白质相容的,pH范围约为4.0至8.5的缓冲液中培育,溶液还包括叔丁醇助溶剂,其中培育在约25℃至约37℃进行约15分钟至约24小时;和
(2)纯化步骤(1)生成的共轭物以生产单体共轭物。
22.根据权利要求21所述的方法,其中X有化学式Z-Sp,其中:
Sp是直链或支链的二价或三价(C1-C18)基团,二价或三价芳基或杂芳基团,二价或三价(C3-C18)的环烷基或杂环烷基基团,二价或三价的芳基-芳基或杂芳基-芳基(C1-C18)基团,二价或三价的环烷基-烷基或杂环烷基-烷基(C1-C18)基团或二价或三价(C2-C18)不饱和烷基基团,其中杂芳基最好是呋喃基,噻嗯基,N-甲基吡咯基,吡啶基,N-甲基咪唑基,噁唑基,嘧啶基,喹啉基,异喹啉基,N-甲基咔唑基,氨基香豆素基,或吩嗪基和其中如果Sp是三价基团,Sp还可被低碳(C1-C5)二烷基氨基,低碳(C1-C5)烷氧基,羟基,或低碳(C1-C5)硫代烷基基团替代;和
23.根据权利要求21所述的方法,其中X有化学式
(CO-Alk1-Sp1-Ar-Sp2-Alk2-C(Z1)=Q-Sp)
其中
Alk1和Alk2各自代表一个键或有支链或无支链的(C1-C10)的亚烷基链;
Sp1是一个键,-S-,-O-,-CONH-,-NHCO-,-NR′-,-N(CH2CH2)2N-,或-X-Ar′-Y-(CH2)n-Z,其中X,Y,和Z各自为一个键,-NR′-,-S-或-O-,限制条件是当n=0时,Y和Z中的至少一个须为一个键,且Ar′是1,2-,1,3-,或1,4-亚苯基,其可任意被(C1-C5)烷基,(C1-C4)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,-O(CH2)nCONHR′,或-S(CH2)nCONHR′中的一个,两个或三个基团取代,限制条件是当Alk1是一个键时,Sp1是一个键;
n是0至5间的整数;
R′是有支链或无支链的(C1-C5)链,它可任意被-OH,(C1-C4)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,(C1-C3)二烷基氨基,或(C1-C3)三烷基铵-A-中的一个或两个基团取代,其中A-是药物学上可接受的成盐阴离子;
Ar是1,2-,1,3-,或1,4-亚苯基,它可任意被(C1-C6)烷基,(C1-C5)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,-O(CH2)nCONHR′,或-S(CH2)nCONHR′中的一个,两个或三个基团取代,其中n和R′是如上所确定的,或Ar为1,2-,1,3-,1,4-,1,5-,1,6-,1,7-,1,8-,2,3-,2,6-,或2,7-亚萘基或
每个亚萘基或吩噻嗪可任意被(C1-C6)烷基,(C1-C5)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′-,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,或-S(CH2)nCONHR′中的一个,两个,三个或四个基团取代,其中n和R′是如上所确定的,限制条件是当Ar是亚萘基时,Z1不是氢,当Ar是吩噻嗪时,Sp1是一个仅与氮连接的键;
Sp2是一个键-S-,或-O-,限制条件是当Alk2是一个键时,Sp2是一个键;
Z1是H,(C1-C5)烷基或苯基,其可任意被(C1-C5)烷基,(C1-C5)烷氧基,(C1-C5)硫代烷氧基,卤素,硝基,-COOR′,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,-O(CH2)nCONHR′,或-S(CH2)nCONHR′中的一个,两个或三个基团取代,其中n和R′是如上所确定;
Sp是直链或支链的二价或三价(C1-C18)基团,二价或三价芳基或杂芳基基团,二价或三价(C3-C18)的环烷基或杂环烷基基团,二价或三价的芳基-芳基或杂芳基-芳基(C1-C18)基团,二价或三价的环烷基-烷基或杂环烷基-烷基(C1-C18)基团或二价或三价(C2-C18)不饱和烷基基团,其中杂芳基最好是呋喃基,噻嗯基,N-甲基吡咯基,吡啶基,N-甲基咪唑基,噁唑基,嘧啶基,喹啉基,异喹啉基,N-甲基咔唑基,氨基香豆素基或吩嗪基,其中如果Sp是三价基团,Sp还可被低碳(C1-C5)二烷基氨基,低碳(C1-C5)烷氧基,羟基,或低碳(C1-C5)硫代烷基基团替代;和
Q是=NHNCO-,=NHNCS-,=NHNCONH-,=NHNCSNH-,或=NHO-。
24.根据权利要求23所述的方法,其中
Sp是一个键,-S-,-O-,-CONH-,-NHCO-或-NR′,其中n和R′如权利要求23所确定的,限制条件是当Alk1是一个键时,Sp1是一个键;
Ar是1,2-,1,3-,或1,4-亚苯基,它可任意被(C1-C6)烷基,(C1-C5)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,-O(CH2)nCONHR′,或-S(CH2)nCONHR′中的一个,两个或三个基团取代,其中n和R′是如权利要求23所确定的,或Ar为1,2-,1,3-,1,4-,1,5-,1,6-,1,7-,1,8-,2,3-,2,6-,或2,7-亚萘基,每个亚萘基可任意被(C1-C6)烷基,(C1-C5)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,-O(CH2)nCONHR′,或-S(CH2)nCONHR′中的一个,两个,三个或四个基团取代;
Alk1是有支链或无支链(C1-C10)亚烷基链;
Z1是(C1-C5)烷基或苯基,它可任意被(C1-C5)烷基,(C1-C4)烷氧基,(C1-C4)硫代烷氧基,卤素,硝基,-COOR′,-CONHR′,-O(CH2)nCOOR′,-S(CH2)nCOOR′,-O(CH2)nCONHR′,或-S(CH2)nCONHR′中的一个,两个或三个基团取代;和
Alk2和Sp2同为一个键。
25.根据权利要求24所述的方法,其中Sp1为-O-,Alk1为C3亚烷基,Ar是1,4-亚苯基,和Z1是C1烷基。
26.根据权利要求23所述的方法,其中Q是=NHNCO-和Sp是-CH2C(CH3)2-。
27.根据权利要求22所述的方法,其中Z是-NHC(=O)-和Sp是-CH2CH2C(CH3)2-。
28.根据权利要求22所述的方法,其中Z是-CH=NNHC(=O)-和Sp是-CH2C(CH3)2-。
29.根据权利要求21所述的方法,其中卡利许霉素衍生物包括一种γ卡利许霉素或一种N-乙酰基γ卡利许霉素衍生物。
30.根据权利要求29所述的方法,其中卡利许霉素衍生物在步骤(1)中的含量为约0.025mg/ml至约1.0mg/ml。
31.根据权利要求21所述的方法,其中蛋白质载体包括一种人化的单克隆抗体。
32.根据权利要求31所述的方法,其中人化的单克隆抗体在步骤(1)中的含量为约1mg/ml至约15mg/ml。
33.根据权利要求21所述的方法,其中步骤(1)中叔丁醇的含量为溶液体积的约10%至约25%。
34.根据权利要求21所述的方法,其中步骤(1)中的叔丁醇的含量为溶液体积的15%。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/475,005 US5712374A (en) | 1995-06-07 | 1995-06-07 | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US08/475,005 | 1995-06-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1186442A CN1186442A (zh) | 1998-07-01 |
CN1094063C true CN1094063C (zh) | 2002-11-13 |
Family
ID=23885856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN96194451A Expired - Fee Related CN1094063C (zh) | 1995-06-07 | 1996-05-10 | 制备单体卡利许霉素衍生物/载体的共轭物的方法 |
Country Status (28)
Country | Link |
---|---|
US (1) | US5712374A (zh) |
EP (1) | EP0837698B1 (zh) |
JP (2) | JPH11508232A (zh) |
KR (1) | KR100499648B1 (zh) |
CN (1) | CN1094063C (zh) |
AR (1) | AR002360A1 (zh) |
AT (1) | ATE204180T1 (zh) |
AU (1) | AU703862B2 (zh) |
BG (1) | BG63492B1 (zh) |
BR (1) | BR9608564A (zh) |
CA (1) | CA2223329A1 (zh) |
CY (1) | CY2355B1 (zh) |
CZ (1) | CZ298024B6 (zh) |
DE (1) | DE69614551T2 (zh) |
DK (1) | DK0837698T3 (zh) |
ES (1) | ES2160818T3 (zh) |
GR (1) | GR3036930T3 (zh) |
HK (1) | HK1016871A1 (zh) |
HU (1) | HU221246B1 (zh) |
IL (1) | IL118565A (zh) |
IN (1) | IN182139B (zh) |
MX (1) | MX9709316A (zh) |
NO (1) | NO324609B1 (zh) |
NZ (1) | NZ307926A (zh) |
PT (1) | PT837698E (zh) |
TW (1) | TW419377B (zh) |
WO (1) | WO1996040261A1 (zh) |
ZA (1) | ZA964614B (zh) |
Families Citing this family (598)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6914130B2 (en) * | 1998-06-17 | 2005-07-05 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20050159588A1 (en) * | 1999-06-02 | 2005-07-21 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
CN101121021B (zh) | 1999-06-25 | 2011-12-07 | 杰南技术公司 | 人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗 |
HUP0300369A2 (hu) | 2000-04-11 | 2003-06-28 | Genentech, Inc. | Többértékű antitestek és alkalmazásuk |
US7129261B2 (en) * | 2001-05-31 | 2006-10-31 | Medarex, Inc. | Cytotoxic agents |
AU2002318169B2 (en) | 2001-06-01 | 2007-10-18 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
US7803915B2 (en) * | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
KR100607612B1 (ko) | 2001-06-20 | 2006-08-02 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
US20050107595A1 (en) * | 2001-06-20 | 2005-05-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
EP1487877B1 (en) | 2001-09-18 | 2010-10-27 | Genentech, Inc. | Compositions and methods for the diagnosis of tumors |
KR20070087247A (ko) | 2002-01-02 | 2007-08-27 | 제넨테크, 인크. | 종양의 진단 및 치료 방법 및 이를 위한 조성물 |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US8093357B2 (en) * | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20090042291A1 (en) * | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
US20100311954A1 (en) * | 2002-03-01 | 2010-12-09 | Xencor, Inc. | Optimized Proteins that Target Ep-CAM |
EP1571968A4 (en) | 2002-04-16 | 2007-10-17 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS |
GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
PT1507556T (pt) * | 2002-05-02 | 2016-09-28 | Wyeth Holdings Llc | Conjugados de derivado da caliqueamicina - transportador |
AU2015246156B2 (en) * | 2002-05-02 | 2017-06-29 | Wyeth Holdings Llc. | Calicheamicin derivative-carrier conjugates |
AU2012244218C1 (en) * | 2002-05-02 | 2016-12-15 | Wyeth Holdings Llc. | Calicheamicin derivative-carrier conjugates |
PL214010B1 (pl) | 2002-07-15 | 2013-06-28 | Genentech Inc | Rekombinowane humanizowane przeciwcialo 2C4 i zastosowanie tego przeciwciala |
DK2345671T3 (en) | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
KR100945327B1 (ko) | 2003-07-08 | 2010-03-08 | 제넨테크, 인크. | Il-17a/f 이종 폴리펩티드 및 그의 치료 용도 |
WO2005012531A2 (en) * | 2003-08-01 | 2005-02-10 | Genentech, Inc. | Antibody cdr polypeptide sequences with restricted diversity |
US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
DK2295073T3 (da) | 2003-11-17 | 2014-07-28 | Genentech Inc | Antistof mod cd22 til behandling af tumor af hæmatopoietisk oprindelse |
PL1718677T3 (pl) | 2003-12-19 | 2012-09-28 | Genentech Inc | Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze |
TW200539855A (en) * | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
NZ550217A (en) | 2004-03-31 | 2009-11-27 | Genentech Inc | Humanized anti-TGF-beta antibodies |
WO2005112919A2 (en) * | 2004-05-19 | 2005-12-01 | Medarex, Inc. | Self-immolative linkers and drug conjugates |
US7691962B2 (en) * | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
KR100863776B1 (ko) | 2004-07-15 | 2008-10-16 | 젠코어 인코포레이티드 | 최적화된 Fc 변이체 |
ZA200701183B (en) | 2004-07-20 | 2008-05-28 | Genentech Inc | Inhibitors of angiopoietin-like 4 protein, combinations, an their use |
JP5226308B2 (ja) | 2004-07-26 | 2013-07-03 | ジェネンテック, インコーポレイテッド | 肝細胞増殖因子活性化を制御するための方法及び組成物 |
US20060045877A1 (en) * | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
ZA200701575B (en) * | 2004-09-03 | 2008-09-25 | Genentech Inc | Humanized anti-betA7 antagonists and uses therefor |
TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP2325206B1 (en) | 2004-11-12 | 2014-03-19 | Xencor, Inc. | Fc variants with altered binding to fcrn |
US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US20070135620A1 (en) * | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
DE602006013275D1 (de) | 2005-01-07 | 2010-05-12 | Diadexus Inc | Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür |
CN101141981A (zh) | 2005-01-21 | 2008-03-12 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
CN101124249B (zh) * | 2005-02-18 | 2011-06-29 | 米德列斯公司 | 抗前列腺特异性膜抗原(psma)的人单克隆抗体 |
ES2440481T3 (es) | 2005-02-23 | 2014-01-29 | Genentech, Inc. | Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab |
WO2006096861A2 (en) * | 2005-03-08 | 2006-09-14 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) |
US8323645B2 (en) | 2005-03-24 | 2012-12-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind OV064 and methods of use therefor |
EP2062591A1 (en) | 2005-04-07 | 2009-05-27 | Novartis Vaccines and Diagnostics, Inc. | CACNA1E in cancer diagnosis detection and treatment |
EP2083088A3 (en) | 2005-04-07 | 2009-10-14 | Novartis Vaccines and Diagnostics, Inc. | Cancer-related genes |
US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
CA2610709A1 (en) | 2005-06-06 | 2006-12-14 | Genentech, Inc. | Transgenic models for different genes and their use for gene characterization |
US20070003559A1 (en) * | 2005-07-01 | 2007-01-04 | Wyeth | Methods of determining pharmacokinetics of targeted therapies |
WO2007008943A2 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
EP1922410A2 (en) | 2005-08-15 | 2008-05-21 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
AU2006297126A1 (en) | 2005-09-30 | 2007-04-12 | Government Of The United States Of America, As Represented By The Secretary | Methods and compositions for modulating immune tolerance |
AU2006299429B2 (en) | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
ATE534629T1 (de) | 2005-10-26 | 2011-12-15 | Medarex Inc | Verfahren und verbindungen zur herstellung von cc-1065-analoga |
EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
CA2630432A1 (en) | 2005-11-21 | 2007-07-19 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
ES2547689T3 (es) | 2005-12-02 | 2015-10-08 | Genentech, Inc. | Composiciones y métodos para el tratamiento de enfermedades y trastornos asociados con la señalización de citocinas que implican anticuerpos que se unen a IL-22 y a IL-22R |
RU2470941C2 (ru) * | 2005-12-02 | 2012-12-27 | Дженентек, Инк. | Связывающие полипептиды и их применения |
EP1973951A2 (en) * | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
EP1957097A1 (en) * | 2005-12-06 | 2008-08-20 | Wyeth a Corporation of the State of Delaware | Interleukin-11 compositions and methods of use |
EP3309170B1 (en) | 2005-12-15 | 2019-05-22 | Genentech, Inc. | Polyubiquitin antibodies |
AU2007248444B2 (en) | 2006-01-05 | 2012-10-25 | Genentech, Inc. | Anti-EphB4 antibodies and methods using same |
EP1988768A2 (en) | 2006-02-17 | 2008-11-12 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
TW200806685A (en) | 2006-02-21 | 2008-02-01 | Wyeth Corp | Processes for the convergent synthesis of calicheamicin derivatives |
WO2007103522A2 (en) | 2006-03-08 | 2007-09-13 | Wake Forest University Health Sciences | Soluble monomeric ephrin a1 |
DK1994055T3 (da) | 2006-03-10 | 2014-08-25 | Wyeth Llc | Anti-5t4-antistoffer og anvendelser deraf |
AR059851A1 (es) | 2006-03-16 | 2008-04-30 | Genentech Inc | Anticuerpos de la egfl7 y metodos de uso |
EP2389950A1 (en) | 2006-03-23 | 2011-11-30 | Novartis AG | Anti-tumor cell antigen antibody therapeutics |
EP2614839A3 (en) | 2006-04-05 | 2015-01-28 | Genentech, Inc. | Method for using BOC/CDO to modulate hedgehog signaling |
EP2407483A1 (en) | 2006-04-13 | 2012-01-18 | Novartis Vaccines and Diagnostics, Inc. | Methods of treating, diagnosing or detecting cancers |
AU2007297565A1 (en) | 2006-04-19 | 2008-03-27 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
RS53168B (en) | 2006-05-30 | 2014-06-30 | Genentech Inc. | Antibodies and Immunoconjugates and Their Use |
SI2059536T1 (sl) | 2006-08-14 | 2014-06-30 | Xencor, Inc. | Optimirana protitelesa, ki ciljajo CD19 |
ES2372217T3 (es) | 2006-09-12 | 2012-01-17 | Genentech, Inc. | Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético. |
PT2845866T (pt) | 2006-10-27 | 2017-08-09 | Genentech Inc | Anticorpos e imunoconjugados e utilizações dos mesmos |
CA2670696A1 (en) | 2006-11-27 | 2008-06-05 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
KR20090114443A (ko) | 2007-02-09 | 2009-11-03 | 제넨테크, 인크. | 항-Robo4 항체 및 그의 용도 |
KR20090122439A (ko) | 2007-02-21 | 2009-11-30 | 메다렉스, 인코포레이티드 | 단일 아미노산을 갖는 화학적 링커 및 이의 접합체 |
CL2008000614A1 (es) * | 2007-03-02 | 2008-09-05 | Genentech Inc F Hoffmann La Ro | Metodo para tratar un paciente con un tipo de cancer que expresa el receptor her3 a un nivel bajo mediante la administracion de un inhibidor de la dimerizacion de her. |
US8846005B2 (en) | 2007-03-14 | 2014-09-30 | Novartis Ag | APCDD1 inhibitors for treating, diagnosing or detecting cancer |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
WO2008150494A1 (en) | 2007-05-30 | 2008-12-11 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
PE20090309A1 (es) * | 2007-06-04 | 2009-04-18 | Wyeth Corp | Conjugado portador-caliqueamicina y un metodo de deteccion de caliqueamicina |
ES2381788T3 (es) | 2007-07-16 | 2012-05-31 | Genentech, Inc. | Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso |
AU2008276128B2 (en) | 2007-07-16 | 2013-10-10 | Genentech, Inc. | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
WO2009041613A1 (ja) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 抗体定常領域改変体 |
DK2220116T3 (da) | 2007-11-12 | 2012-11-26 | Theraclone Sciences Inc | Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza |
US20110033476A1 (en) * | 2007-11-12 | 2011-02-10 | Theraclone Sciences Inc. | Compositions and methods for the therapy and diagnosis of influenza |
TWI468417B (zh) | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗-vegf抗體 |
JP2011507933A (ja) * | 2007-12-26 | 2011-03-10 | バイオテスト・アクチエンゲゼルシヤフト | 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法 |
CA3086659A1 (en) | 2007-12-26 | 2009-07-09 | Xencor, Inc. | Fc variants with altered binding to fcrn |
HUE024291T2 (en) * | 2007-12-26 | 2016-01-28 | Biotest Ag | Immunoconjugates and Applications for CD138 |
KR101626416B1 (ko) * | 2007-12-26 | 2016-06-01 | 바이오테스트 아게 | Cd138 표적 물질 및 이의 용도 |
RU2486203C2 (ru) * | 2007-12-26 | 2013-06-27 | Биотест Аг | Способы улучшения направленного воздействия на cd138-экспрессирующие опухолевые клетки и агенты для их осуществления |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
IL287292B (en) | 2008-01-31 | 2022-09-01 | Genentech Inc | and fusion antibody-drug-cd79b engineered antibodies cysteine- |
WO2009114560A2 (en) * | 2008-03-10 | 2009-09-17 | Spaltudaq Corporation | Compositions and methods for the therapy and diagnosis of cytomegalovirus |
NZ601815A (en) * | 2008-03-31 | 2014-10-31 | Genentech Inc | Compositions and methods for treating and diagnosing asthma |
KR101924831B1 (ko) | 2008-04-09 | 2018-12-05 | 제넨테크, 인크. | 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법 |
CA2723614C (en) * | 2008-05-16 | 2015-07-14 | Genentech, Inc. | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists |
DK2318832T3 (da) | 2008-07-15 | 2014-01-20 | Academia Sinica | Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder |
AR073717A1 (es) | 2008-10-01 | 2010-11-24 | Genentech Inc | Anticuerpos anti-notch2 de murino y humano, y metodos de uso |
EP2376117A1 (en) | 2008-12-17 | 2011-10-19 | Genentech, Inc. | Hepatitis c virus combination therapy |
EP2396347B1 (en) | 2009-02-11 | 2017-04-12 | Albumedix A/S | Albumin variants and conjugates |
SI3260136T1 (sl) | 2009-03-17 | 2021-05-31 | Theraclone Sciences, Inc. | Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa |
CN102356092B (zh) | 2009-03-20 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
CN104788564A (zh) | 2009-03-25 | 2015-07-22 | 健泰科生物技术公司 | 抗-fgfr3抗体及其使用方法 |
TWI504409B (zh) | 2009-03-25 | 2015-10-21 | Genentech Inc | 新穎抗-α5β1抗體及其用途 |
CA2757382A1 (en) | 2009-04-01 | 2010-10-21 | Kristi Elkins | Anti-fcrh5 antibodies and immunoconjugates |
CN102369215B (zh) | 2009-04-02 | 2015-01-21 | 罗切格利卡特公司 | 包含全长抗体和单链Fab片段的多特异性抗体 |
CN102439040B (zh) | 2009-04-16 | 2017-05-03 | 艾伯维生物医疗股份有限公司 | 抗TNF‑α抗体和其用途 |
US9296785B2 (en) | 2009-04-17 | 2016-03-29 | Wake Forest University Health Sciences | IL-13 receptor binding peptides |
SG175305A1 (en) * | 2009-04-23 | 2011-11-28 | Theraclone Sciences Inc | Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies |
RU2016142225A (ru) | 2009-05-13 | 2018-12-18 | Джензим Корпорейшн | Иммуноглобулины к cd52 человека |
CA2762302A1 (en) | 2009-05-20 | 2010-11-25 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
MX338775B (es) | 2009-06-04 | 2016-05-02 | Novartis Ag | Metodos para identificacion de sitios para conjugacion de igg. |
CA2765755C (en) | 2009-06-17 | 2018-01-02 | Abbott Biotherapeutics Corp. | Anti-vegf antibodies and their uses |
ES2513292T3 (es) | 2009-07-31 | 2014-10-24 | Genentech, Inc. | Inhibición de metástasis tumoral usando anticuerpos anti-G-CSF |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
DK2473522T3 (en) | 2009-09-02 | 2016-11-28 | Genentech Inc | Smoothened MUTANT AND METHODS OF USING THE SAME |
BR112012005893A2 (pt) | 2009-09-16 | 2016-11-22 | Genentech Inc | hélice enrolada e/ou complexos de proteínas contendo conectores e usos dos mesmos |
ES2552157T3 (es) | 2009-10-16 | 2015-11-26 | Novartis Ag | Biomarcadores de respuesta farmacodinámica tumoral |
KR20120106940A (ko) * | 2009-10-19 | 2012-09-27 | 제넨테크, 인크. | 간세포 성장 인자 활성화제의 조절제 |
CN102711826B (zh) | 2009-10-22 | 2017-03-29 | 霍夫曼-拉罗奇有限公司 | 用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物 |
US8435511B2 (en) | 2009-10-22 | 2013-05-07 | Genentech, Inc. | Anti-hepsin antibodies and methods using same |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
TW201122101A (en) | 2009-10-28 | 2011-07-01 | Facet Biotech Corp | Anti-EGFR antibodies and their uses |
GB2488077A (en) | 2009-10-30 | 2012-08-15 | Novozymes Biopharma Dk As | Albumin variants |
US8361744B2 (en) | 2009-11-05 | 2013-01-29 | Genentech, Inc. | Methods and composition for secretion of heterologous polypeptides |
WO2011066503A2 (en) | 2009-11-30 | 2011-06-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
CA2781682A1 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
ES2557454T3 (es) | 2009-12-10 | 2016-01-26 | F. Hoffmann-La Roche Ag | Anticuerpos que se unen al dominio extracelular 4 de CSF1R humana y su utilización |
US8486397B2 (en) | 2009-12-11 | 2013-07-16 | Genentech, Inc. | Anti-VEGF-C antibodies and methods using same |
ES2594893T3 (es) | 2009-12-16 | 2016-12-23 | Abbvie Biotherapeutics Inc. | Anticuerpos anti HER2 y sus usos |
JP5852010B2 (ja) | 2009-12-23 | 2016-02-03 | ジェネンテック, インコーポレイテッド | 抗Bv8抗体およびその使用 |
WO2011089211A1 (en) | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
KR20130000384A (ko) | 2010-02-18 | 2013-01-02 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 뉴레귤린 길항제 및 암의 치료에서의 그의 용도 |
KR20130004579A (ko) | 2010-02-23 | 2013-01-11 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 조성물 및 방법 |
EP2542587A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
EP2542588A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
TW201134481A (en) | 2010-03-12 | 2011-10-16 | Abbott Biotherapeutics Corp | CTLA4 proteins and their uses |
US8846041B2 (en) | 2010-03-24 | 2014-09-30 | Genentech, Inc. | Anti-LRP6 antibodies |
AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
JP5969458B2 (ja) | 2010-04-09 | 2016-08-17 | アルブミディクス アクティーゼルスカブ | アルブミン誘導体及び変異体 |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
CA2796633C (en) | 2010-04-23 | 2020-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
MX342239B (es) | 2010-05-03 | 2016-09-21 | Genentech Inc * | Composiciones y metodos para el diagnostico y tratamiento de tumores. |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
MX370828B (es) | 2010-05-25 | 2020-01-08 | Genentech Inc | Métodos de purificación de polipéptidos. |
RU2613886C2 (ru) | 2010-06-03 | 2017-03-21 | Дженентек, Инк. | Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения |
RU2755066C2 (ru) | 2010-06-08 | 2021-09-13 | Дженентек, Инк. | Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты |
AR082017A1 (es) | 2010-06-18 | 2012-11-07 | Genentech Inc | Anticuerpos anti-axl (receptor de tirosina quinasas) y metodos de uso |
WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
WO2011161189A1 (en) | 2010-06-24 | 2011-12-29 | F. Hoffmann-La Roche Ag | Anti-hepsin antibodies and methods of use |
CN103052649B (zh) | 2010-07-29 | 2015-12-16 | Xencor公司 | 具有修改的等电点的抗体 |
CA2806855A1 (en) | 2010-08-03 | 2012-02-09 | F. Hoffmann - La Roche Ag | Chronic lymphocytic leukemia (cll) biomarkers |
AU2011289275A1 (en) | 2010-08-12 | 2013-02-21 | Theraclone Sciences, Inc. | Anti-hemagglutinin antibody compositions and methods of use thereof |
MX2013001336A (es) | 2010-08-13 | 2013-03-08 | Roche Glycart Ag | Anticuerpos ani-tenascina c a2 y metodos de utilizacion. |
MX358859B (es) | 2010-08-13 | 2018-09-05 | Roche Glycart Ag | Anticuerpos anti-fap y métodos de utilización. |
JP2013537539A (ja) | 2010-08-13 | 2013-10-03 | ジェネンテック, インコーポレイテッド | 疾患の治療のためのIL−1β及びIL−18に対する抗体 |
CA2807278A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann - La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
EP3556396B1 (en) | 2010-08-31 | 2022-04-20 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv)-neutralizing antibodies |
KR20130103734A (ko) | 2010-08-31 | 2013-09-24 | 제넨테크, 인크. | 바이오마커 및 치료 방법 |
RU2013115927A (ru) | 2010-09-10 | 2014-10-20 | Апексиджен, Инк. | АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ |
EA201790850A1 (ru) | 2010-09-29 | 2017-11-30 | Эдженсис, Инк. | Конъюгаты антитело-лекарственное средство (adc), связывающиеся с белками 191p4d12 |
US9228023B2 (en) | 2010-10-01 | 2016-01-05 | Oxford Biotherapeutics Ltd. | Anti-ROR1 antibodies and methods of use for treatment of cancer |
DK2625197T3 (en) | 2010-10-05 | 2016-10-03 | Genentech Inc | Smoothened MUTANT AND METHODS OF USING THE SAME |
SG190682A1 (en) | 2010-11-10 | 2013-07-31 | Genentech Inc | Methods and compositions for neural disease immunotherapy |
EP3447491A3 (en) | 2010-12-16 | 2019-06-05 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to th2 inhibition |
MA34881B1 (fr) | 2010-12-20 | 2014-02-01 | Genentech Inc | Anticorps et immunoconjugués anti-mésothéline |
AR084456A1 (es) | 2010-12-22 | 2013-05-15 | Genentech Inc | Anticuerpo anti-pcsk9 y metodos de uso |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
BR112013019499B1 (pt) | 2011-02-04 | 2023-01-10 | Genentech, Inc. | Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
WO2012109624A2 (en) | 2011-02-11 | 2012-08-16 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
TW201245223A (en) | 2011-02-14 | 2012-11-16 | Theraclone Sciences Inc | Compositions and methods for the therapy and diagnosis of influenza |
BR112013021863A2 (pt) | 2011-03-03 | 2016-11-22 | Apexigen Inc | anticorpos anti-receptor il-6 e métodos de uso |
US8609818B2 (en) | 2011-03-10 | 2013-12-17 | Omeros Corporation | Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution |
JP2014509591A (ja) | 2011-03-15 | 2014-04-21 | セラクローン サイエンシーズ, インコーポレイテッド | インフルエンザの治療および診断のための組成物および方法 |
HUE041335T2 (hu) | 2011-03-29 | 2019-05-28 | Roche Glycart Ag | Antitest FC-variánsok |
EP2694551A1 (en) | 2011-04-07 | 2014-02-12 | Genentech, Inc. | Anti-fgfr4 antibodies and methods of use |
CA2828662A1 (en) | 2011-04-20 | 2012-10-26 | Roche Glycart Ag | Method and constructs for the ph dependent passage of the blood-brain-barrier |
EP3508500A1 (en) | 2011-04-29 | 2019-07-10 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
EP2710035B1 (en) | 2011-05-16 | 2017-04-12 | F. Hoffmann-La Roche AG | Fgfr1 agonists and methods of use |
AU2012258637B2 (en) | 2011-05-24 | 2017-07-20 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
KR101972446B1 (ko) | 2011-05-27 | 2019-04-25 | 글락소 그룹 리미티드 | Bcma(cd269/tnfrsf17)결합 단백질 |
SG194932A1 (en) | 2011-06-30 | 2013-12-30 | Genentech Inc | Anti-c-met antibody formulations |
WO2013022855A1 (en) | 2011-08-05 | 2013-02-14 | Xencor, Inc. | Antibodies with modified isoelectric points and immunofiltering |
EP3392274A1 (en) | 2011-08-12 | 2018-10-24 | Omeros Corporation | Anti-fzd10 monoclonal antibodies and methods for their use |
EP2744825A1 (en) | 2011-08-17 | 2014-06-25 | F.Hoffmann-La Roche Ag | Inhibition of angiogenesis in refractory tumors |
EP2744824A1 (en) | 2011-08-17 | 2014-06-25 | F.Hoffmann-La Roche Ag | Neuregulin antibodies and uses thereof |
JP6060162B2 (ja) | 2011-08-23 | 2017-01-11 | ロシュ グリクアート アーゲー | 2つのFabフラグメントを含むFc不含抗体および使用方法 |
EP2747781B1 (en) | 2011-08-23 | 2017-11-15 | Roche Glycart AG | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
US8822651B2 (en) | 2011-08-30 | 2014-09-02 | Theraclone Sciences, Inc. | Human rhinovirus (HRV) antibodies |
WO2013040433A1 (en) | 2011-09-15 | 2013-03-21 | Genentech, Inc. | Methods of promoting differentiation |
RU2014114617A (ru) | 2011-09-19 | 2015-10-27 | Дженентек, Инк. | Комбинированные виды лечения, содержащие антагонисты с-мет и антагонисты b-raf |
KR101684750B1 (ko) | 2011-09-23 | 2016-12-08 | 로슈 글리카트 아게 | 이중특이적 항-egfr/항-igf-1r 항체 |
AU2012319150B2 (en) | 2011-10-05 | 2017-08-17 | Genentech, Inc. | Methods of treating liver conditions using Notch2 antagonists |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
CA2851534C (en) | 2011-10-10 | 2023-02-14 | Xencor, Inc. | A method for purifying antibodies |
CN103974709B (zh) | 2011-10-14 | 2016-12-14 | 霍夫曼-拉罗奇有限公司 | Bace1的肽抑制剂 |
PT2766393T (pt) | 2011-10-14 | 2018-10-15 | Hoffmann La Roche | Anticorpos anti-htra1 e métodos de utilização |
JP6254087B2 (ja) | 2011-10-15 | 2017-12-27 | ジェネンテック, インコーポレイテッド | 癌を治療するためのscd1アンタゴニスト |
CN104039340B (zh) | 2011-10-28 | 2017-04-05 | 霍夫曼-拉罗奇有限公司 | 治疗黑素瘤的方法及治疗剂组合 |
DK2773438T4 (da) | 2011-11-02 | 2022-01-03 | Hoffmann La Roche | Overladnings- og elueringskromatografi |
TWI571473B (zh) | 2011-11-02 | 2017-02-21 | 埃派斯進有限公司 | 抗kdr抗體及使用方法 |
EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
MX2014005885A (es) | 2011-11-21 | 2014-09-04 | Genentech Inc | Purificacion de anticuerpos anti-c-met. |
CN104302324A (zh) | 2011-12-08 | 2015-01-21 | 生物测试股份公司 | 靶向cd138的免疫偶联物的用途 |
WO2013087699A1 (en) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
US20130195851A1 (en) | 2011-12-23 | 2013-08-01 | Genentech, Inc. | Articles of manufacture and methods for co-administration of antibodies |
JP2015509091A (ja) | 2012-01-09 | 2015-03-26 | ザ スクリプス リサーチ インスティテュート | ヒト化抗体 |
EP2802603A4 (en) | 2012-01-09 | 2015-11-04 | Scripps Research Inst | REGIONS DETERMINING ULTRALONGUAL COMPLEMENTARYITY AND USES THEREOF |
CN104168920A (zh) | 2012-01-18 | 2014-11-26 | 霍夫曼-拉罗奇有限公司 | 使用fgf19调控剂的方法 |
AU2013209707A1 (en) | 2012-01-18 | 2014-07-24 | Genentech, Inc. | Anti-LRP5 antibodies and methods of use |
EP2812357B1 (en) | 2012-02-10 | 2020-11-04 | F.Hoffmann-La Roche Ag | Single-chain antibodies and other heteromultimers |
SG11201404703WA (en) | 2012-02-11 | 2014-09-26 | Genentech Inc | R-spondin translocations and methods using the same |
ES2676031T3 (es) | 2012-02-15 | 2018-07-16 | F. Hoffmann-La Roche Ag | Cromatografía de afinidad basada en el receptor Fc |
CA2861592A1 (en) | 2012-03-16 | 2013-09-19 | Novozymes Biopharma Dk A/S | Albumin variants |
AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
MX2014012889A (es) | 2012-05-01 | 2014-11-14 | Genentech Inc | Anticuerpos e inmunoconjugados anti-pmel17. |
WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
RU2015101113A (ru) | 2012-06-15 | 2016-08-10 | Дженентек, Инк. | Антитела против pcsk9, составы, дозы и способы применения |
MX2014014065A (es) | 2012-06-27 | 2015-02-04 | Hoffmann La Roche | Metodo para la seleccion y produccion de moleculas terapeuticas hechas a la medida, selectivas y multiespecificas que comprenden al menos dos diferentes entidades de direccionamiento y usos de las mismas. |
CN104411718B (zh) | 2012-06-27 | 2018-04-24 | 弗·哈夫曼-拉罗切有限公司 | 用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途 |
CN104395339A (zh) | 2012-06-27 | 2015-03-04 | 弗·哈夫曼-拉罗切有限公司 | 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途 |
SI2869837T1 (sl) | 2012-07-04 | 2016-12-30 | F. Hoffmann-La Roche Ag | Protitelesa proti teofilinu in postopki uporabe |
RU2630296C2 (ru) | 2012-07-04 | 2017-09-06 | Ф. Хоффманн-Ля Рош Аг | Антитела к биотину и способы их применения |
NZ701040A (en) | 2012-07-04 | 2017-02-24 | Hoffmann La Roche | Covalently linked antigen-antibody conjugates |
IN2014DN11157A (zh) | 2012-07-13 | 2015-10-02 | Roche Glycart Ag | |
EP2885311B1 (en) | 2012-08-18 | 2020-01-01 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
KR102355959B1 (ko) | 2012-08-23 | 2022-01-27 | 어젠시스 인코포레이티드 | 158p1d7 단백질에 결합하는 항체 약물 컨쥬게이트(adc) |
BR112015005857A2 (pt) | 2012-09-19 | 2017-08-08 | Abbvie Biotherapeutics Inc | métodos para identificação de anticorpos com imunogenicidade reduzida |
BR112015007120A2 (pt) | 2012-10-08 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo |
CN109265552A (zh) | 2012-10-30 | 2019-01-25 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
US10189906B2 (en) | 2012-11-01 | 2019-01-29 | Max-Delrück-Centrum Für Molekulare Medizin | Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
AU2013343503B2 (en) | 2012-11-08 | 2017-12-14 | Albumedix Ltd. | Albumin variants |
EP2917243B1 (en) | 2012-11-08 | 2018-03-14 | F.Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
ES2701746T3 (es) | 2012-11-13 | 2019-02-25 | Hoffmann La Roche | Anticuerpos antihemaglutinina y procedimientos de uso |
JP2015537212A (ja) | 2012-11-15 | 2015-12-24 | ジェネンテック, インコーポレイテッド | イオン強度媒介のph勾配イオン交換クロマトグラフィー |
EP2922818B1 (en) | 2012-11-24 | 2018-09-05 | Hangzhou Dac Biotech Co., Ltd | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
WO2014107739A1 (en) | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
KR102391731B1 (ko) | 2013-01-14 | 2022-04-27 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
AU2014207549B2 (en) | 2013-01-15 | 2018-12-06 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
CN104994879A (zh) | 2013-02-22 | 2015-10-21 | 霍夫曼-拉罗奇有限公司 | 治疗癌症和预防药物抗性的方法 |
MX2015010789A (es) | 2013-02-26 | 2015-11-26 | Roche Glycart Ag | Anticuerpos anti-pcsm. |
JP2016510751A (ja) | 2013-03-06 | 2016-04-11 | ジェネンテック, インコーポレイテッド | 抗がん剤耐性を治療及び予防する方法 |
CA2905070A1 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
KR20150127199A (ko) | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | 항-b7-h4 항체 및 면역접합체 |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
US20160143910A1 (en) | 2013-03-15 | 2016-05-26 | Constellation Pharmaceuticals, Inc. | Methods of treating cancer and preventing cancer drug resistance |
KR20150128707A (ko) | 2013-03-15 | 2015-11-18 | 제넨테크, 인크. | 간암의 진단 및 치료를 위한 조성물 및 방법 |
CN105451767B (zh) | 2013-03-15 | 2019-10-18 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
CA2906927C (en) | 2013-03-15 | 2021-07-13 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
BR112015021521A2 (pt) | 2013-03-15 | 2017-10-10 | Genentech Inc | anticorpos anti-crth2 e métodos para seu uso |
CN105143257B (zh) | 2013-03-15 | 2020-10-27 | 艾伯维生物医疗股份有限公司 | Fc变体 |
WO2014145806A2 (en) | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Heterodimeric proteins |
US20150010538A1 (en) | 2013-03-15 | 2015-01-08 | Abbvie Biotherapeutics Inc. | Anti-cd25 antibodies and their uses |
KR102158924B1 (ko) | 2013-03-15 | 2020-09-22 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
US20150010539A1 (en) | 2013-03-15 | 2015-01-08 | Abbvie Biotherapeutics Inc. | Anti-cd25 antibodies and their uses |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
KR102233349B1 (ko) | 2013-03-15 | 2021-03-31 | 에이씨 이뮨 에스.에이. | 항-타우(tau) 항체 및 사용 방법 |
AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
RU2019108429A (ru) | 2013-04-29 | 2019-05-06 | Ф. Хоффманн-Ля Рош Аг | Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения |
WO2014179657A1 (en) | 2013-05-03 | 2014-11-06 | Eleven Biotherapeutics, Inc. | Albumin variants binding to fcrn |
US9708406B2 (en) | 2013-05-20 | 2017-07-18 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
US10086054B2 (en) | 2013-06-26 | 2018-10-02 | Academia Sinica | RM2 antigens and use thereof |
US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
SG11201600221YA (en) | 2013-07-12 | 2016-02-26 | Genentech Inc | Elucidation of ion exchange chromatography input optimization |
EP3022224A2 (en) | 2013-07-18 | 2016-05-25 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
JP6687520B2 (ja) | 2013-07-18 | 2020-04-22 | トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー | 極めて長い相補性決定領域を有するヒト化抗体 |
TWI646108B (zh) | 2013-08-01 | 2019-01-01 | 艾澤西公司 | 結合至cd37蛋白質之抗體藥物結合物(adc) |
WO2015035044A2 (en) | 2013-09-04 | 2015-03-12 | Abbvie Biotherapeutics Inc. | Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY |
CA2922832A1 (en) | 2013-09-05 | 2015-03-12 | Genentech, Inc. | Method for chromatography reuse |
EP3041484B1 (en) | 2013-09-06 | 2021-03-03 | Academia Sinica | Human inkt cell activation using glycolipids with altered glycosyl groups |
AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
CN105518027A (zh) | 2013-09-17 | 2016-04-20 | 豪夫迈·罗氏有限公司 | 使用抗lgr5抗体的方法 |
PT3055331T (pt) | 2013-10-11 | 2021-04-05 | Oxford Bio Therapeutics Ltd | Anticorpos conjugados contra ly75 para o tratamento de cancro |
CA2925598A1 (en) | 2013-10-18 | 2015-04-23 | Genentech, Inc. | Anti-rspo antibodies and methods of use |
KR20160072268A (ko) | 2013-11-04 | 2016-06-22 | 화이자 인코포레이티드 | 항-efna4 항체-약물 접합체 |
SG11201604784XA (en) | 2013-12-13 | 2016-07-28 | Genentech Inc | Anti-cd33 antibodies and immunoconjugates |
WO2015095227A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
TWI670283B (zh) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | 抗體及使用方法 |
EP3960768A1 (en) | 2014-01-03 | 2022-03-02 | F. Hoffmann-La Roche AG | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
CA2930154A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
CA2930046A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Covalently linked polypeptide toxin-antibody conjugates |
US10023892B2 (en) | 2014-05-27 | 2018-07-17 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
KR20160104727A (ko) | 2014-01-16 | 2016-09-05 | 아카데미아 시니카 | 암의 치료 및 검출을 위한 조성물 및 방법 |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
AU2015209154A1 (en) | 2014-01-24 | 2017-02-16 | Genentech, Inc. | Methods of using anti-STEAP1 antibodies and immunoconjugates |
ES2694857T3 (es) | 2014-02-04 | 2018-12-27 | Genentech, Inc. | Smoothened mutante y métodos de uso de la misma |
AU2015217271B2 (en) | 2014-02-12 | 2018-10-25 | Genentech, Inc. | Anti-Jagged1 antibodies and methods of use |
KR20160124165A (ko) | 2014-02-21 | 2016-10-26 | 제넨테크, 인크. | 항-il-13/il-17 이중특이적 항체 및 그의 용도 |
DK3122757T3 (da) | 2014-02-28 | 2023-10-09 | Hangzhou Dac Biotech Co Ltd | Ladede linkere og anvendelse deraf til konjugering |
SI3116999T1 (sl) | 2014-03-14 | 2021-12-31 | F. Hoffmann - La Roche Ag | Postopki in sestavki za izločanje heterolognih polipeptidov |
AR099812A1 (es) | 2014-03-21 | 2016-08-17 | Abbvie Inc | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr |
RU2016141385A (ru) | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
JP6562942B2 (ja) | 2014-03-27 | 2019-08-28 | アカデミア シニカAcademia Sinica | 反応性標識化合物およびその使用 |
KR20230022270A (ko) | 2014-03-28 | 2023-02-14 | 젠코어 인코포레이티드 | Cd38 및 cd3에 결합하는 이중특이적 항체 |
SG11201607969XA (en) | 2014-03-31 | 2016-10-28 | Genentech Inc | Anti-ox40 antibodies and methods of use |
JP6588461B2 (ja) | 2014-03-31 | 2019-10-09 | ジェネンテック, インコーポレイテッド | 抗血管新生剤及びox40結合アゴニストを含む併用療法 |
KR20160143808A (ko) | 2014-04-11 | 2016-12-14 | 메디뮨 엘엘씨 | 이중특이적 her2 항체 |
WO2015171822A1 (en) | 2014-05-06 | 2015-11-12 | Genentech, Inc. | Production of heteromultimeric proteins using mammalian cells |
KR20170003582A (ko) | 2014-05-22 | 2017-01-09 | 제넨테크, 인크. | 항-gpc3 항체 및 면역접합체 |
MX2016015163A (es) | 2014-05-23 | 2017-03-03 | Genentech Inc | Biomarcadores mit y metodos para su uso. |
KR20170003720A (ko) | 2014-05-27 | 2017-01-09 | 아카데미아 시니카 | 항-cd20 글리코항체 및 이의 용도 |
KR102512592B1 (ko) | 2014-05-27 | 2023-03-21 | 아카데미아 시니카 | 항-her2 글리코항체 및 이의 용도 |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
US11332523B2 (en) | 2014-05-28 | 2022-05-17 | Academia Sinica | Anti-TNF-alpha glycoantibodies and uses thereof |
US20230190750A1 (en) | 2014-06-13 | 2023-06-22 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
EP3164419A1 (en) | 2014-06-26 | 2017-05-10 | F. Hoffmann-La Roche AG | Anti-brdu antibodies and methods of use |
WO2016007775A1 (en) | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Notch pathway inhibition |
EP3194449A1 (en) | 2014-07-24 | 2017-07-26 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
DK3186284T3 (da) | 2014-08-28 | 2022-05-09 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
US9879042B2 (en) | 2014-09-08 | 2018-01-30 | Academia Sinica | Human iNKT cell activation using glycolipids |
EP3191518B1 (en) | 2014-09-12 | 2020-01-15 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
SG11201701128YA (en) | 2014-09-12 | 2017-03-30 | Genentech Inc | Cysteine engineered antibodies and conjugates |
MX2017003022A (es) | 2014-09-12 | 2017-05-12 | Genentech Inc | Anticuerpos anti-cll-1 e inmunoconjugados. |
ES2830385T3 (es) | 2014-09-12 | 2021-06-03 | Genentech Inc | Anticuerpos e inmunoconjugados anti-HER2 |
RS60349B8 (sr) | 2014-09-23 | 2022-10-31 | Hoffmann La Roche | Postupak upotrebe anti-cd79b imunokonjugata |
JP6863888B2 (ja) | 2014-10-01 | 2021-04-21 | メディミューン,エルエルシー | ポリペプチドをコンジュゲートさせる方法 |
JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック, インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
EP3212665A2 (en) | 2014-10-31 | 2017-09-06 | F. Hoffmann-La Roche AG | Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same |
EP3215637B1 (en) | 2014-11-03 | 2019-07-03 | F. Hoffmann-La Roche AG | Methods and biomarkers for predicting efficacy and valuation of an ox40 agonist treatment |
US20160161485A1 (en) | 2014-11-03 | 2016-06-09 | Genentech, Inc. | Assays for detecting t cell immune subsets and methods of use thereof |
CA2961439A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
WO2016073157A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
ES2749383T3 (es) | 2014-11-06 | 2020-03-20 | Hoffmann La Roche | Variantes de la región Fc con unión al FcRn modificada y procedimientos de uso |
MX2017006094A (es) | 2014-11-10 | 2017-07-19 | Genentech Inc | Anticuerpos anti-interleucina-33 y sus usos. |
CN107001473B (zh) | 2014-11-19 | 2021-07-09 | 豪夫迈·罗氏有限公司 | 抗-运铁蛋白受体抗体及使用方法 |
CN107250158B (zh) | 2014-11-19 | 2022-03-25 | 基因泰克公司 | 抗转铁蛋白受体/抗bace1多特异性抗体和使用方法 |
WO2016081639A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Antibodies against bace1 and use thereof for neural disease immunotherapy |
AU2015353409B2 (en) | 2014-11-26 | 2019-05-09 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
TN2017000222A1 (en) | 2014-11-26 | 2018-10-19 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cd38 |
EP3227332B1 (en) | 2014-12-03 | 2019-11-06 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
HUE045216T2 (hu) | 2014-12-05 | 2019-12-30 | Hoffmann La Roche | Anti-CD79B antitestek és alkalmazási eljárások |
WO2016094566A2 (en) | 2014-12-10 | 2016-06-16 | Genentech, Inc. | Blood brain barrier receptor antibodies and methods of use |
TW201809008A (zh) | 2014-12-19 | 2018-03-16 | 日商中外製藥股份有限公司 | 抗c5抗體及使用方法 |
WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
ES2818103T3 (es) | 2015-01-16 | 2021-04-09 | Juno Therapeutics Inc | Anticuerpos y receptores de antígenos quiméricos específicos para ROR1 |
CN107428823B (zh) | 2015-01-22 | 2021-10-26 | 中外制药株式会社 | 两种以上抗-c5抗体的组合与使用方法 |
KR102630294B1 (ko) | 2015-01-24 | 2024-01-26 | 아카데미아 시니카 | 암 마커 및 이를 사용하는 방법 |
AU2015378564A1 (en) | 2015-01-24 | 2017-07-13 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
WO2016126972A1 (en) | 2015-02-04 | 2016-08-11 | Genentech, Inc. | Mutant smoothened and methods of using the same |
EP3816179A3 (en) | 2015-02-05 | 2021-08-04 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant comprising a modified fcrn-binding domain |
WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
EP3913052A1 (en) | 2015-04-24 | 2021-11-24 | F. Hoffmann-La Roche AG | Methods of identifying bacteria comprising binding polypeptides |
AU2016252773B2 (en) | 2015-04-24 | 2022-06-02 | Genentech, Inc. | Multispecific antigen-binding proteins |
EP3288981A1 (en) | 2015-05-01 | 2018-03-07 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
CN107592812A (zh) | 2015-05-11 | 2018-01-16 | 豪夫迈·罗氏有限公司 | 治疗狼疮性肾炎的组合物和方法 |
JP7048319B2 (ja) | 2015-05-12 | 2022-04-05 | ジェネンテック, インコーポレイテッド | 癌のための治療方法及び診断方法 |
MX2017015011A (es) | 2015-05-28 | 2018-03-23 | Genentech Inc | Ensayo a base de celulas para detectar homodimeros anti-cd3. |
IL255372B (en) | 2015-05-29 | 2022-07-01 | Genentech Inc | Therapeutic and diagnostic methods for cancer |
JP2018520658A (ja) | 2015-05-29 | 2018-08-02 | ジェネンテック, インコーポレイテッド | ヒト化抗エボラウイルス糖タンパク質抗体及びその使用 |
KR20180025888A (ko) | 2015-06-08 | 2018-03-09 | 제넨테크, 인크. | 항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법 |
KR20180011839A (ko) | 2015-06-08 | 2018-02-02 | 제넨테크, 인크. | 항-ox40 항체를 이용한 암의 치료 방법 |
HRP20231134T1 (hr) | 2015-06-16 | 2024-01-05 | F. Hoffmann - La Roche Ag | Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu |
WO2016205200A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cll-1 antibodies and methods of use |
JP2018526972A (ja) | 2015-06-16 | 2018-09-20 | ジェネンテック, インコーポレイテッド | 抗cd3抗体及び使用方法 |
JP2018524312A (ja) | 2015-06-17 | 2018-08-30 | ジェネンテック, インコーポレイテッド | 抗her2抗体及び使用方法 |
BR112017024610A2 (pt) | 2015-06-24 | 2018-07-31 | F. Hoffmann-La Roche Ag | anticorpos para receptor antitransferrina com afinidade especificada |
AU2016285596A1 (en) | 2015-06-29 | 2018-01-18 | Genentech, Inc. | Type II anti-CD20 antibody for use in organ transplantation |
CA2991973C (en) | 2015-07-12 | 2021-12-07 | Suzhou M-Conj Biotech Co., Ltd. | Bridge linkers for conjugation of a cell-binding molecule |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
AU2016301361B2 (en) | 2015-08-05 | 2022-06-16 | Janssen Biotech, Inc. | Anti-CD154 antibodies and methods of using them |
CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
JP7007261B2 (ja) | 2015-08-20 | 2022-01-24 | アルブミディクス リミティド | アルブミン変異体及びコンジュゲート |
US10072075B2 (en) | 2015-09-23 | 2018-09-11 | Genentech, Inc. | Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis |
US11142565B2 (en) | 2015-09-24 | 2021-10-12 | Abvitro Llc | Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope |
WO2017053748A2 (en) | 2015-09-25 | 2017-03-30 | Genentech, Inc. | Anti-tigit antibodies and methods of use |
US10544229B2 (en) | 2015-09-30 | 2020-01-28 | Janssen Biotech, Inc. | Agonistic antibodies specifically binding CD40 and methods of use |
KR102146319B1 (ko) | 2015-10-02 | 2020-08-25 | 에프. 호프만-라 로슈 아게 | Pd1 및 tim3에 특이적인 이중특이성 항체 |
PE20181092A1 (es) | 2015-10-02 | 2018-07-09 | Hoffmann La Roche | Anticuerpos anti-pd1 y metodos de uso |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
CN114031689A (zh) | 2015-10-02 | 2022-02-11 | 豪夫迈·罗氏有限公司 | 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法 |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
WO2017066714A1 (en) | 2015-10-16 | 2017-04-20 | Compugen Ltd. | Anti-vsig1 antibodies and drug conjugates |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
SI3368579T1 (sl) | 2015-10-30 | 2022-04-29 | F.Hoffmann-La Roche Ag | Tečajni modificirani fragmenti protitelesa in metode priprave |
EP3370768B9 (en) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
EP3371217A1 (en) | 2015-11-08 | 2018-09-12 | H. Hoffnabb-La Roche Ag | Methods of screening for multispecific antibodies |
US11623957B2 (en) | 2015-12-07 | 2023-04-11 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
CA2997406A1 (en) | 2015-12-09 | 2017-06-15 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release |
CA3005592C (en) | 2015-12-18 | 2024-01-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
CN109073635A (zh) | 2016-01-25 | 2018-12-21 | 豪夫迈·罗氏有限公司 | 用于测定t细胞依赖性双特异性抗体的方法 |
WO2017132298A1 (en) | 2016-01-27 | 2017-08-03 | Medimmune, Llc | Methods for preparing antibodies with a defined glycosylation pattern |
AU2017213826A1 (en) | 2016-02-04 | 2018-08-23 | Curis, Inc. | Mutant smoothened and methods of using the same |
AU2017225854B2 (en) | 2016-02-29 | 2020-11-19 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
EP3426693A4 (en) | 2016-03-08 | 2019-11-13 | Academia Sinica | PROCESS FOR MODULAR SYNTHESIS OF N-GLYCANES AND ARRANGEMENTS THEREOF |
US20170319688A1 (en) | 2016-04-14 | 2017-11-09 | Genentech, Inc. | Anti-rspo3 antibodies and methods of use |
JP7002467B2 (ja) | 2016-04-15 | 2022-01-20 | マクロジェニクス,インコーポレーテッド | 新規のb7‐h3結合分子、その抗体薬物コンジュゲート、及びその使用方法 |
CN109154027A (zh) | 2016-04-15 | 2019-01-04 | 豪夫迈·罗氏有限公司 | 用于监测和治疗癌症的方法 |
JP6735355B2 (ja) | 2016-04-15 | 2020-08-05 | バイオアトラ、エルエルシー | 抗Axl抗体、抗体断片およびそれらの免疫コンジュゲートならびにそれらの使用 |
EP3443350B1 (en) | 2016-04-15 | 2020-12-09 | H. Hoffnabb-La Roche Ag | Methods for monitoring and treating cancer |
BR112018069890A2 (pt) | 2016-05-02 | 2019-02-05 | Hoffmann La Roche | polipeptídio de fusão que se liga de forma específica a um alvo, polipeptídio de fusão dimérico, ácido nucleico isolado, par de ácidos nucleicos isolados, célula hospedeira, método para produzir um polipeptídio de fusão, imunoconjugado, formulação farmacêutica, polipeptídio de fusão e uso do polipeptídio de fusão |
WO2017196847A1 (en) | 2016-05-10 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens |
WO2017194441A1 (en) | 2016-05-11 | 2017-11-16 | F. Hoffmann-La Roche Ag | Modified anti-tenascin antibodies and methods of use |
IL262404B2 (en) | 2016-05-13 | 2024-04-01 | Bioatla Llc | Antibodies, Antibody Fragments and Their Immunomodules Against ROR2 and Their Uses |
CN109313200B (zh) | 2016-05-27 | 2022-10-04 | 豪夫迈·罗氏有限公司 | 用于表征位点特异性抗体-药物缀合物的生物分析性方法 |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
CA3059010A1 (en) | 2016-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
WO2017214182A1 (en) | 2016-06-07 | 2017-12-14 | The United States Of America. As Represented By The Secretary, Department Of Health & Human Services | Fully human antibody targeting pdi for cancer immunotherapy |
US20200338209A1 (en) | 2016-06-08 | 2020-10-29 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
AU2017277914A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-CD98 antibodies and antibody drug conjugates |
CN109563167A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
AU2017279550A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-B7-H3 antibodies and antibody drug conjugates |
FI3468997T3 (fi) | 2016-06-08 | 2023-10-31 | Xencor Inc | Igg4:ään liittyvien sairauksien hoito anti-cd19-vasta-aineilla, jotka ristisitoutuvat cd32b:een |
MX2018015272A (es) | 2016-06-08 | 2019-08-12 | Abbvie Inc | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. |
MX2018015592A (es) | 2016-06-14 | 2019-04-24 | Xencor Inc | Anticuerpos inhibidores de puntos de control biespecificos. |
JP7021127B2 (ja) | 2016-06-28 | 2022-02-16 | ゼンコア インコーポレイテッド | ソマトスタチン受容体2に結合するヘテロ二量体抗体 |
MA45784A (fr) | 2016-07-29 | 2019-06-05 | Juno Therapeutics Inc | Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps |
CA3031559A1 (en) | 2016-08-02 | 2018-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof |
TW202300168A (zh) | 2016-08-05 | 2023-01-01 | 日商中外製藥股份有限公司 | Il-8相關疾病之治療用或預防用組成物 |
WO2018027204A1 (en) | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
EP3497440A1 (en) | 2016-08-15 | 2019-06-19 | H. Hoffnabb-La Roche Ag | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide |
TWI764917B (zh) | 2016-08-22 | 2022-05-21 | 醣基生醫股份有限公司 | 抗體、結合片段及使用方法 |
WO2018036852A1 (en) | 2016-08-25 | 2018-03-01 | F. Hoffmann-La Roche Ag | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
EP3515932B1 (en) | 2016-09-19 | 2023-11-22 | F. Hoffmann-La Roche AG | Complement factor based affinity chromatography |
MX2019003934A (es) | 2016-10-06 | 2019-07-10 | Genentech Inc | Métodos terapéuticos y de diagnóstico para el cáncer. |
AU2017342560B2 (en) | 2016-10-14 | 2022-03-17 | Xencor, Inc. | IL15/IL15Ralpha heterodimeric Fc-fusion proteins |
CN110267678A (zh) | 2016-10-29 | 2019-09-20 | 霍夫曼-拉罗奇有限公司 | 抗mic抗体和使用方法 |
CA3042442C (en) | 2016-11-14 | 2024-01-02 | Hangzhou Dac Biotech Co., Ltd | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses of such conjugates with the linkers |
US11466094B2 (en) | 2016-11-15 | 2022-10-11 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
JP7313684B2 (ja) | 2016-11-21 | 2023-07-25 | キュレアブ ゲーエムベーハー | 抗gp73抗体及びイムノコンジュゲート |
CA3045902A1 (en) | 2016-12-21 | 2018-06-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for flt3 and uses thereof |
CN110072553B (zh) | 2016-12-22 | 2023-09-15 | 豪夫迈·罗氏有限公司 | 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗 |
UA126574C2 (uk) | 2017-02-10 | 2022-11-02 | Дженентек, Інк. | Антитіло проти триптази, його композиція та застосування |
PL3589754T3 (pl) | 2017-03-01 | 2023-10-09 | F. Hoffmann-La Roche Ag | Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych |
MX2019012793A (es) | 2017-04-27 | 2020-02-13 | Tesaro Inc | Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos. |
AU2018268970A1 (en) | 2017-05-19 | 2019-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibody targeting tnfr2 for cancer immunotherapy |
AR111963A1 (es) | 2017-05-26 | 2019-09-04 | Univ California | Método y moléculas |
EP3645122A1 (en) | 2017-06-30 | 2020-05-06 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains |
CA3066953A1 (en) | 2017-06-30 | 2019-01-03 | Lentigen Technology, Inc. | Human monoclonal antibodies specific for cd33 and methods of their use |
WO2019005208A1 (en) | 2017-06-30 | 2019-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY |
US11674962B2 (en) | 2017-07-21 | 2023-06-13 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
US20210190764A1 (en) | 2017-10-20 | 2021-06-24 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring cellular uptake of molecules |
BR112020007736A2 (pt) | 2017-10-30 | 2020-10-20 | F. Hoffmann-La Roche Ag | composição e método de tratamento |
MX2020004243A (es) | 2017-11-01 | 2020-09-25 | Juno Therapeutics Inc | Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b. |
JP2021500930A (ja) | 2017-11-01 | 2021-01-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Compボディ−多価標的結合物質 |
MX2020004196A (es) | 2017-11-01 | 2020-11-09 | Hoffmann La Roche | Trifab-contorsbody. |
MX2020004567A (es) | 2017-11-06 | 2020-08-13 | Genentech Inc | Metodos diagnosticos y terapeuticos para el cancer. |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
EP3706793A1 (en) | 2017-11-08 | 2020-09-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
KR20200100098A (ko) | 2017-12-19 | 2020-08-25 | 젠코어 인코포레이티드 | 조작된 il-2 fc 융합 단백질 |
US11667713B2 (en) | 2017-12-28 | 2023-06-06 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
US20200339686A1 (en) | 2018-01-16 | 2020-10-29 | Lakepharma, Inc. | Bispecific antibody that binds cd3 and another target |
AR115360A1 (es) | 2018-02-08 | 2021-01-13 | Genentech Inc | Moléculas de unión al antígeno y métodos de uso |
KR20200135313A (ko) | 2018-02-26 | 2020-12-02 | 제넨테크, 인크. | 항-tigit 및 항-pd-l1 길항제 항체에 의한 치료를 위한 투약 |
US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
SG11202009010RA (en) | 2018-03-15 | 2020-10-29 | Chugai Pharmaceutical Co Ltd | Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use |
EP3778639A4 (en) | 2018-04-02 | 2021-06-09 | Mab-Venture Biopharm Co., Ltd. | ANTIBODIES BINDING TO LYMPHOCYTAIR ACTIVATION GENE 3 (LAG-3) AND ITS USE |
TW202011029A (zh) | 2018-04-04 | 2020-03-16 | 美商建南德克公司 | 偵測及定量fgf21之方法 |
AU2019247415A1 (en) | 2018-04-04 | 2020-10-22 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
KR20210003814A (ko) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질 |
AR114789A1 (es) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
SG11202010163QA (en) | 2018-04-18 | 2020-11-27 | Xencor Inc | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
AU2019271147A1 (en) | 2018-05-14 | 2020-12-17 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
KR20210021467A (ko) | 2018-05-14 | 2021-02-26 | 웨어울프 세라퓨틱스, 인크. | 활성화가능한 인터루킨-2 폴리펩타이드 및 이의 사용 방법 |
US11746157B2 (en) | 2018-05-24 | 2023-09-05 | Janssen Biotech, Inc. | PSMA binding agents and uses thereof |
EP3817770A2 (en) | 2018-07-02 | 2021-05-12 | Amgen Inc. | Anti-steap1 antigen-binding protein |
US11939377B2 (en) | 2018-07-12 | 2024-03-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Affinity matured CD22-specific monoclonal antibody and uses thereof |
CA3106544A1 (en) | 2018-08-08 | 2020-02-13 | Mitchell Ho | High affinity monoclonal antibodies targeting glypican-2 and uses thereof |
SG10202106830VA (en) | 2018-08-10 | 2021-08-30 | Chugai Pharmaceutical Co Ltd | Anti-cd137 antigen-binding molecule and utilization thereof |
CA3111401A1 (en) | 2018-09-19 | 2020-03-26 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
EP4321530A3 (en) | 2018-09-27 | 2024-05-22 | Xilio Development, Inc. | Masked cytokine polypeptides |
MX2021003765A (es) | 2018-10-03 | 2021-07-15 | Xencor Inc | Proteínas il-12 de fusión a fc heterodimérico. |
MX2021004348A (es) | 2018-10-18 | 2021-05-28 | Genentech Inc | Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide. |
CA3119798A1 (en) | 2018-12-06 | 2020-06-11 | Genentech, Inc. | Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody |
WO2020127968A1 (en) | 2018-12-20 | 2020-06-25 | Marino Stephen F | Protein-drug conjugate comprising a monomeric form of proteinase 3 |
TW202035442A (zh) | 2018-12-20 | 2020-10-01 | 美商建南德克公司 | 經修飾之抗體Fc及其使用方法 |
WO2020139926A2 (en) | 2018-12-26 | 2020-07-02 | Akrevia Therapeutics Inc. | Anti-ctla4 antibodies and methods of use thereof |
CA3125484A1 (en) | 2019-01-08 | 2020-07-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cross-species single domain antibodies targeting mesothelin for treating solid tumors |
JP2022522985A (ja) | 2019-01-22 | 2022-04-21 | ジェネンテック, インコーポレイテッド | 免疫グロブリンa抗体、並びに産生及び使用の方法 |
US20220098323A1 (en) | 2019-01-22 | 2022-03-31 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
EP3915581A4 (en) | 2019-01-24 | 2023-03-22 | Chugai Seiyaku Kabushiki Kaisha | NOVEL CANCER ANTIGENS AND ANTIBODIES OF THESE ANTIGENS |
PE20212198A1 (es) | 2019-01-29 | 2021-11-16 | Juno Therapeutics Inc | Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1) |
MX2021010313A (es) | 2019-02-27 | 2021-09-23 | Genentech Inc | Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38. |
EP3930850A1 (en) | 2019-03-01 | 2022-01-05 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
EP3938403A1 (en) | 2019-03-14 | 2022-01-19 | F. Hoffmann-La Roche AG | Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab |
EP3956664A1 (en) | 2019-04-18 | 2022-02-23 | Genentech, Inc. | Antibody potency assay |
KR20220002899A (ko) | 2019-04-19 | 2022-01-07 | 얀센 바이오테크 인코포레이티드 | 항-psma/cd3 항체로 전립선암을 치료하는 방법 |
CA3134522A1 (en) | 2019-04-19 | 2020-10-22 | Genentech, Inc. | Anti-mertk antibodies and their methods of use |
CA3138045C (en) | 2019-05-14 | 2024-02-20 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma |
AU2020275877A1 (en) | 2019-05-14 | 2021-12-23 | Werewolf Therapeutics, Inc. | Separation moieties and methods and use thereof |
MX2021013441A (es) | 2019-05-15 | 2021-12-10 | Chugai Pharmaceutical Co Ltd | Molecula de union a antigenos, composicion farmaceutica y metodo. |
AR119264A1 (es) | 2019-06-05 | 2021-12-09 | Genentech Inc | Método para reutilización de cromatografía |
TW202116805A (zh) | 2019-07-10 | 2021-05-01 | 日商中外製藥股份有限公司 | Claudin-6結合分子以及其用途 |
JPWO2021010326A1 (zh) | 2019-07-12 | 2021-01-21 | ||
AU2020351734A1 (en) | 2019-09-27 | 2022-04-14 | Genentech, Inc. | Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies |
WO2021076196A1 (en) | 2019-10-18 | 2021-04-22 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
CA3156761A1 (en) | 2019-10-22 | 2021-04-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors |
IL292458A (en) | 2019-11-06 | 2022-06-01 | Genentech Inc | Diagnostic and treatment methods for the treatment of hematological cancer |
CN115916817A (zh) | 2019-12-06 | 2023-04-04 | 朱诺治疗学股份有限公司 | 针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法 |
JP2023504736A (ja) | 2019-12-06 | 2023-02-06 | ジュノー セラピューティクス インコーポレイテッド | Gprc5d標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法 |
JP2023506158A (ja) | 2019-12-12 | 2023-02-15 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Cd276に特異的な抗体-薬物コンジュゲートおよびその使用 |
MX2022007158A (es) | 2019-12-13 | 2022-07-11 | Genentech Inc | Anticuerpos anti-ly6g6d y metodos de uso. |
KR102645629B1 (ko) | 2019-12-27 | 2024-03-07 | 추가이 세이야쿠 가부시키가이샤 | 항ctla-4 항체 및 그의 사용 |
CN110818795B (zh) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
TW202144395A (zh) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
TW202144410A (zh) | 2020-03-13 | 2021-12-01 | 美商建南德克公司 | 抗介白素-33抗體及其用途 |
CR20220524A (es) | 2020-03-19 | 2022-12-02 | Genentech Inc | Anticuerpos anti-tgf-beta con selectividad de isoforma y métodos de uso |
JP2023520515A (ja) | 2020-04-03 | 2023-05-17 | ジェネンテック, インコーポレイテッド | がんに対する治療方法及び診断方法 |
CA3175530A1 (en) | 2020-04-24 | 2021-10-28 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates |
JP2023523450A (ja) | 2020-04-28 | 2023-06-05 | ジェネンテック, インコーポレイテッド | 非小細胞肺がん免疫療法のための方法及び組成物 |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
WO2021252977A1 (en) | 2020-06-12 | 2021-12-16 | Genentech, Inc. | Methods and compositions for cancer immunotherapy |
IL298946A (en) | 2020-06-18 | 2023-02-01 | Genentech Inc | Treatment with anti-TIGIT antibodies and PD-1 spindle-binding antagonists |
CA3188000A1 (en) | 2020-07-13 | 2022-01-20 | Genentech, Inc. | Cell-based methods for predicting polypeptide immunogenicity |
WO2022025184A1 (ja) | 2020-07-29 | 2022-02-03 | 中外製薬株式会社 | 非放射性物質で標識した薬剤の薬物動態を測定する方法 |
KR20230095918A (ko) | 2020-08-05 | 2023-06-29 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법 |
CN115836122A (zh) | 2020-08-07 | 2023-03-21 | 基因泰克公司 | 用于预测多肽免疫原性的基于t细胞的方法 |
CN116234830A (zh) | 2020-08-07 | 2023-06-06 | 基因泰克公司 | Flt3配体融合蛋白及使用方法 |
WO2022076462A1 (en) | 2020-10-05 | 2022-04-14 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
US20230391852A1 (en) | 2020-10-26 | 2023-12-07 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting sars coronavirus spike protein and uses thereof |
US20240000846A1 (en) | 2020-10-27 | 2024-01-04 | Vor Biopharma Inc. | Compositions and methods for treating hematopoietic malignancy |
KR20230100732A (ko) | 2020-11-04 | 2023-07-05 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이성 항체의 피하 투여 |
IL302217A (en) | 2020-11-04 | 2023-06-01 | Genentech Inc | Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies and anti-CD79B drug antibody conjugates |
TW202225192A (zh) | 2020-11-04 | 2022-07-01 | 美商建南德克公司 | 用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
CA3210246A1 (en) | 2021-01-28 | 2022-08-04 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
TW202246324A (zh) | 2021-03-01 | 2022-12-01 | 美商艾希利歐發展股份有限公司 | 用於治療癌症的經掩蔽之ctla4及pd1/pdl1抗體之組合 |
EP4301467A1 (en) | 2021-03-01 | 2024-01-10 | Xilio Development, Inc. | Combination of ctla4 and pd1/pdl1 antibodies for treating cancer |
AU2022232375A1 (en) | 2021-03-09 | 2023-09-21 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
AR125344A1 (es) | 2021-04-15 | 2023-07-05 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-c1s |
WO2022232612A1 (en) | 2021-04-29 | 2022-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lassa virus-specific nanobodies and methods of their use |
TW202243689A (zh) | 2021-04-30 | 2022-11-16 | 瑞士商赫孚孟拉羅股份公司 | 抗cd20/抗cd3雙特異性抗體及抗cd78b抗體藥物結合物的組合治療之給藥 |
KR20240005722A (ko) | 2021-04-30 | 2024-01-12 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이적 항체를 사용한 치료를 위한 투약 |
IL308351A (en) | 2021-05-12 | 2024-01-01 | Genentech Inc | Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma |
WO2022244838A1 (ja) | 2021-05-19 | 2022-11-24 | 中外製薬株式会社 | 分子のin vivo薬物動態を予測する方法 |
EP4347656A1 (en) | 2021-05-28 | 2024-04-10 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapies for treating cancer |
EP4155321A1 (en) | 2021-06-04 | 2023-03-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-ddr2 antibodies and uses thereof |
CN117500831A (zh) | 2021-06-09 | 2024-02-02 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体 |
EP4361176A1 (en) | 2021-06-25 | 2024-05-01 | Chugai Seiyaku Kabushiki Kaisha | Use of anti-ctla-4 antibody |
JP7472405B2 (ja) | 2021-06-25 | 2024-04-22 | 中外製薬株式会社 | 抗ctla-4抗体 |
US11807685B2 (en) | 2021-08-05 | 2023-11-07 | The Uab Research Foundation | Anti-CD47 antibody and uses thereof |
TW202337499A (zh) | 2021-08-07 | 2023-10-01 | 美商建南德克公司 | 使用抗cd79b免疫結合物治療瀰漫性大b細胞淋巴瘤之方法 |
US11987641B2 (en) | 2021-08-27 | 2024-05-21 | Janssen Biotech, Inc. | Anti-PSMA antibodies and uses thereof |
TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法 |
WO2023057893A1 (en) | 2021-10-05 | 2023-04-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapies for treating cancer |
TW202323810A (zh) | 2021-10-08 | 2023-06-16 | 日商中外製藥股份有限公司 | 預填充式注射器製劑的調製方法 |
TW202337904A (zh) | 2022-01-07 | 2023-10-01 | 美商壯生和壯生企業創新公司 | IL-1β結合蛋白之材料及方法 |
WO2023180353A1 (en) | 2022-03-23 | 2023-09-28 | F. Hoffmann-La Roche Ag | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
US20230364020A1 (en) | 2022-04-01 | 2023-11-16 | Genentech, Inc. | Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
JP2024517042A (ja) | 2022-04-13 | 2024-04-19 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗cd20/抗cd3二重特異性抗体の薬学的組成物及び使用方法 |
US20230406930A1 (en) | 2022-04-13 | 2023-12-21 | Genentech, Inc. | Pharmaceutical compositions of therapeutic proteins and methods of use |
US20230346862A1 (en) | 2022-05-02 | 2023-11-02 | Athanor Biosciences, Inc. | Cancer eradicating - bio-nanoparticles (ce-bnp) |
WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2023245105A1 (en) | 2022-06-17 | 2023-12-21 | Genentech, Inc. | Use of kosmotropes to enhance yield of an affinity chromatography purification step |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020432A1 (en) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
WO2024049949A1 (en) | 2022-09-01 | 2024-03-07 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
WO2024073751A1 (en) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
WO2024091991A1 (en) | 2022-10-25 | 2024-05-02 | Genentech, Inc. | Therapeutic and diagnostic methods for multiple myeloma |
WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5053394A (en) * | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5094849A (en) * | 1988-08-08 | 1992-03-10 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0040506B1 (en) * | 1980-05-21 | 1986-08-20 | Teijin Limited | Reactive polymer and process for the preparation thereof |
SE8102193L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och dess anvendning |
CA1203164A (en) * | 1982-03-09 | 1986-04-15 | Thomas J. Mckearn | Antibody conjugates |
US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US4466951A (en) * | 1982-11-12 | 1984-08-21 | University Of California | Intracellular trapping of therapeutics or tracer agents |
US4530835A (en) * | 1983-07-08 | 1985-07-23 | Warner-Lambert Company | CL-1577 Antibiotic compounds and their production |
EP0174816B1 (en) * | 1984-09-10 | 1990-05-23 | Ajinomoto Co., Inc. | Biphenyl-based diester compounds and liquid crystal compositions containing same |
US4970198A (en) * | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
US5160723A (en) * | 1985-04-19 | 1992-11-03 | Sloan-Kettering Institute For Cancer Research | Method of imaging colorectal carcinoma lesion and composition for use therein |
US5431897A (en) * | 1985-04-19 | 1995-07-11 | Sloan-Kettering Institute For Cancer Research | Method of imaging colorectal carcinoma lesion and composition for use therein |
FR2584293B1 (fr) * | 1985-07-04 | 1989-03-17 | Ire Celltarg Sa | Anticorps utiles comme agents de pilotage et conjugues les incorporant |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5037651A (en) * | 1987-01-30 | 1991-08-06 | American Cyanamid Company | Dihydro derivatives of LL-E33288 antibiotics |
US5079233A (en) * | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
DE3735871A1 (de) * | 1987-10-23 | 1989-05-03 | Schoeller F Jun Gmbh Co Kg | Fotografisches traegermaterial fuer lichtempfindliche schichten in form eines kunststoffbeschichteten papiers oder einer kunststoffolie mit einer rueckseitenbeschichtung |
ES2059464T3 (es) * | 1987-10-30 | 1994-11-16 | American Cyanamid Co | Formas especificamente dirigidas de agentes antitumorales de metiltritio. |
EP0329184A3 (en) * | 1988-02-19 | 1990-05-23 | Neorx Corporation | Antimers and antimeric conjugation |
US5028697A (en) * | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
IL93733A (en) * | 1989-04-14 | 1996-01-19 | American Cyanamid Co | History of Dissolved Drug Sulphides Antibacterial and Antibacterial, Prepared from Compounds Containing Methyl-Thriteo Groups and Their Target Form |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5155210A (en) * | 1990-09-11 | 1992-10-13 | Brunswick Corporation | Methods of conjugating actinomycin d |
GB9120467D0 (en) * | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
EP0628077B1 (en) * | 1992-12-10 | 2002-03-20 | Celltech Therapeutics Limited | Humanised antibodies directed against a33 antigen |
US5461068A (en) * | 1993-09-29 | 1995-10-24 | Corwood Laboratories, Inc. | Imidazole derivative tincture and method of manufacture |
US5773001A (en) * | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
-
1995
- 1995-06-07 US US08/475,005 patent/US5712374A/en not_active Expired - Lifetime
-
1996
- 1996-05-10 PT PT96915718T patent/PT837698E/pt unknown
- 1996-05-10 ES ES96915718T patent/ES2160818T3/es not_active Expired - Lifetime
- 1996-05-10 MX MX9709316A patent/MX9709316A/es not_active IP Right Cessation
- 1996-05-10 WO PCT/US1996/006738 patent/WO1996040261A1/en active IP Right Grant
- 1996-05-10 AU AU57423/96A patent/AU703862B2/en not_active Ceased
- 1996-05-10 DE DE69614551T patent/DE69614551T2/de not_active Expired - Fee Related
- 1996-05-10 CZ CZ0393997A patent/CZ298024B6/cs not_active IP Right Cessation
- 1996-05-10 AT AT96915718T patent/ATE204180T1/de not_active IP Right Cessation
- 1996-05-10 CN CN96194451A patent/CN1094063C/zh not_active Expired - Fee Related
- 1996-05-10 KR KR1019970708934A patent/KR100499648B1/ko not_active IP Right Cessation
- 1996-05-10 JP JP9500547A patent/JPH11508232A/ja active Pending
- 1996-05-10 EP EP96915718A patent/EP0837698B1/en not_active Expired - Lifetime
- 1996-05-10 CA CA002223329A patent/CA2223329A1/en not_active Abandoned
- 1996-05-10 NZ NZ307926A patent/NZ307926A/en not_active IP Right Cessation
- 1996-05-10 HU HU9901351A patent/HU221246B1/hu not_active IP Right Cessation
- 1996-05-10 BR BR9608564A patent/BR9608564A/pt not_active Application Discontinuation
- 1996-05-10 DK DK96915718T patent/DK0837698T3/da active
- 1996-06-04 IL IL11856596A patent/IL118565A/en not_active IP Right Cessation
- 1996-06-04 ZA ZA9604614A patent/ZA964614B/xx unknown
- 1996-06-04 IN IN1032CA1996 patent/IN182139B/en unknown
- 1996-06-06 AR ARP960102996A patent/AR002360A1/es active IP Right Grant
- 1996-07-19 TW TW085108822A patent/TW419377B/zh not_active IP Right Cessation
-
1997
- 1997-12-03 BG BG102100A patent/BG63492B1/bg unknown
- 1997-12-05 NO NO19975706A patent/NO324609B1/no not_active IP Right Cessation
-
1998
- 1998-12-30 HK HK98119234A patent/HK1016871A1/xx not_active IP Right Cessation
-
2001
- 2001-10-18 GR GR20010401797T patent/GR3036930T3/el not_active IP Right Cessation
-
2003
- 2003-01-22 CY CY0300018A patent/CY2355B1/xx unknown
-
2008
- 2008-09-08 JP JP2008230053A patent/JP2009073832A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5094849A (en) * | 1988-08-08 | 1992-03-10 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers |
US5053394A (en) * | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1094063C (zh) | 制备单体卡利许霉素衍生物/载体的共轭物的方法 | |
CN105026574B (zh) | 细胞系 | |
Yamada et al. | Recent Chemical Approaches for Site‐Specific Conjugation of Native Antibodies: Technologies toward Next‐Generation Antibody–Drug Conjugates | |
CN1182870C (zh) | 结合稳定的治疗剂组合物、传递和诊断制剂 | |
EP0080401B1 (fr) | Nouveaux médicaments anticancéreux pour le traitement des leucémies T constitués de la chaine A de la ricine et d'un anticorps monoclonal spécifique | |
CN1191093C (zh) | Dds化合物及其测定方法 | |
EP0063988B1 (fr) | Médicaments anticancéreux contenant la chaîne A de la ricine associée à un anticorps antimélanome et procédé pour leur préparation | |
US7928205B2 (en) | Methods for refolding of recombinant antibodies | |
CN1173183A (zh) | 含有水溶性聚合物的bdnf与nt-3的结合物 | |
CN1236370A (zh) | 化学修饰的多肽 | |
CN106604741A (zh) | 酶法制备同质的抗体‑药物缀合物 | |
CN1608079A (zh) | 化学修饰的人生长激素缀合物 | |
CN1252807A (zh) | 新糖蛋白 | |
JPH07196925A (ja) | Pegヒドラゾンおよびpegオキシム結合形成試薬およびそれらのタンパク質誘導体 | |
US20070021591A1 (en) | Compositions and methods for protein deaggregation | |
CN87108348A (zh) | 免疫球蛋白结合物 | |
CN1056056A (zh) | 控制胆固醇的组合物及其控制方法 | |
CN111534475B (zh) | 一种细胞表面偶联抗体的方法及其应用 | |
JPS59116232A (ja) | 細胞毒性複合体及びその製造法 | |
CN1129737A (zh) | 基因转移的修饰蛋白及其制备方法 | |
CN107849121B (zh) | 封端和未封端的抗体半胱氨酸,及其在抗体-药物缀合中的用途 | |
Yuan et al. | Site-selective lysine acetylation of human immunoglobulin G for immunoliposomes and bispecific antibody complexes | |
EP0325270A2 (en) | Anticancer conjugates | |
CN1735428A (zh) | 伴侣蛋白10的免疫抑制作用 | |
CN1219130A (zh) | 用于治疗眼部炎症的含硝酮化合物的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: WYETH(AMERICAN HOME PRODUCTS) HOLDING CO., LTD. Free format text: FORMER NAME OR ADDRESS: AMERICAN CYANAMID COMPANY |
|
CP01 | Change in the name or title of a patent holder |
Patentee after: Wyeth Holding Corp. Patentee before: American Cyanamid Co. |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20021113 Termination date: 20100510 |